KRPIA Value of New Medicine Social Contribution Directory New Medicine New New Hope Korean Research-based Korean Industry Pharmaceutical Association Annual Report 2017

2017 KRPIA Annual Report Message from the Chairman

Greetings!

I would like to thank everyone who has shown end- less interest in Korea Research-based Pharmaceuti- cal Industry Association(KRPIA) for the development of pharmaceutical industry, which to be the emerging driving force in the era of the 4th Industrial Revolution.

For last 18 years, KRPIA has put utmost effort on devel- oping healthcare system and reinforcing the leadership of pharmaceutical industry in Korea. This year, KRPIA changed its Korean name as ‘Ko- rean Global Pharmaceutical Industry Association’, and refreshed our vows to contribute on promoting the people’s health by developing and supplying innovative new drugs, and globalizing Korea’s pharmaceutical industry.

KRPIA and its member companies especially value bettering the health and quality of life of Korean patients, social responsibility, and leveraging Korean pharmaceutical “KRPIA Is Dedicated to Sustainable, Healthier Lives industry’s reputation, and to document such effort, we have published the ‘2017 KRPIA Annual Report’. through the Development of Innovative New Medicine.” The report includes information on social, financial and industrial values of innovative new drug, mutual collaboration with Korean pharmaceutical companies, global phar- maceutical companies’ CSR activities as a corporate citizen, and member company de- tails. The report contains KRPIA’s hope to contribute as a responsible member of Kore- an pharmaceutical industry, and to mutual grow with the Korean society.

The pharmaceutical industry is a collection of the 4th Industrial Revolution based technology, and also a future growth engine with potential to create quality jobs and high value-added business. The world is striving to secure new economic driving force through pharmaceutical industry. Korea is also on a crucial crossroad to leap as a phar- maceutical powerhouse.

KRPIA and global pharmaceutical companies would continue to strive for the Korean pharmaceutical industry to reach the new turning point with endless growth. Moreo- ver, KRPIA aims to serve its role on lessening patients’ burden while encouraging their hopes by supporting the government’s NHI coverage enhancement plan.

I sincerely hope you will continue to give KRPIA your interest and support.

Thank you.

November, 2017 Oak-yeon Kim, Chair

2 2017 KRPIA Annual Report VALUE OF NEW MEDICINE SOCIAL CONTRIBUTION Creating Happiness and Patient Benefit Through New Drug Development Social Contribution Through New Drug Supply and Global Expansion Cooperation

Medical Expenses Prolonging expected life Reduction expectancy with new drug Domestically Amount of Available Medicine Donation

Investment in Reduced Medical New Drug Expenses Coporate Social 13% Drugs in Korea +1$ -7$ Contribution 01 Amount of national social Longevity & Effect of New Cardiovascular Drugs value generated when death Quality of Life about 1,200 KRW 24.7billion rate reduced by 1% (‘16, 27 companies)

Drug Decreases Hospital About KRW Spending Expenditure by Marketing 48 trillion to 126 trillion R&D Open +24$ -89$ Collaboration in Innovation The benefit of innovative 02 Overseas Markets new drug Reduced Medical Market Size of Expenses Pharmaceutical Industry Win-Win Pharmaceutical Industry Collaboration Open Innovation Automobile Industry Cancer death rate reduced by Semi-conductor Industry

25% 1,200 Abott Korea•CTC Bio: License agreement for the 3 incrementally modified new drugs within Asia Abott Korea•CTC Bio: Co-development of Anti-ulcer Combination Drug New drug increases hepatitis C Bayer Korea•Dong-A ST: Co-promotion of ‘Tedizolid,‘ an antibiotic for super bacteria, in overseas AbbVie•DongA ST: Collaboration with Dong-A-ST for MerTK inhibitors in pre-clinical markets(excluding America and Europe) development for use in conjunction with immuno-oncology therapies complete cure rate by 600 400 GSK Korea•Dong-A Socio Holdings: Investment in shares AstraZeneca Korea: Conducting Asia’s first comprehensive clinical study and pre-clinical Lilly Korea•Hanmi Pharmaceutical: Exclusive license and collaboration agreement for the study projects jointly with research teams in Korea 133% development and commercialization of HM71224, treatment of autoimmune and other disease BMS Pharmaceutical Korea Ltd.: Master Clinical Trial Agreement with clinical trial institutions 03 (Unit: KRW trillion) Janssen•Hanmi Pharmaceurtical: Collaboration agreement on technology export for co- in Korea Future Growth development and commercialization of diabetes/obesity treatment GSK Korea: Pre-clinical study in new candidate compounds for anti-cancer drugs jointly with Cancer patients returning Annual Drug Export MSD•Dong-A ST: Co-promotion of ‘Tedizolid,‘ an antibiotic for super bacteria, in overseas major research institutions Engine markets(America and Europe) Janssen Korea: MOU with MOHW: investing $80 million for R&D for severe and infectious to society by innovative diseases and expansion of academic exchange programs over the next 5 years(2014~2018) Annual average increase of 11.5% MSD•Hanmi Pharmaceutical: Investment in R&D of ‘Cozaar XQ ,‘ a combined treatment for anticancer treatment hypertension, and partnership for exporting it to over 50 countries Lilly Korea: Agreement with the Korea Research Institute of Chemical Technology through the MSD•Samsung Bioepis: Collaboration agreement for global commercialization of biosimilar Open Innovation Drug Discovery Program products with Samsung Bioepis MSD Korea Ltd.: ‘Science Ambassador’-Collaborative research across the world and obtained Mundipharma Korea•Genewel: Collaboration with Genewel for licensing, distribution and 250 licenses in Asia promotion of Medifoam®, a moist wound dressing product Novartis: KOTRA Global Partnering Conference sanofi-aventis Korea•Hanmi Pharmaceutical: In discussions for overseas expansion of ‘Rovelito,‘ Pfizer Pharmaceuticals Korea Ltd.: Signed MOU with Korea's Ministry of Health and Welfare the Korea‘s first ARB-Statin combination drug for research and development(R&D), contributed to domestic new drug development and 80% of cancer patients Sanofi•Hanmi Pharmaceutical: A worldwide license agreement to develop a portfolio of healthcare infrastructure research(2008-present) 2.3 2.3 2.5 3.3 3.6 experimental, long-acting diabetes treatments Servier Korea: Partnership with Korea Drug Development Fund(KDDF) returned to workplace Sanofi•LG Chem: Licensing of diabetic treatment ‘Zemiglo‘ in about 70 countries sanofi-aventis Korea: Joint research on diseases prevalent among Asian people within a year after cancer Zuellig Pharma Korea•Boryung Pharm: Exclusive licensing agreement for Kanarb, ARB medicine Sanofi Pasteur Ltd.: A long-term strategic cooperation for the co-development of an diagnosis 2012 2013 2014 2015 2016 for high blood pressure, in 13 Southeast Asian countries innovative Pneumococcal Conjugate Vaccine(PCV).(Collaboration with SK Chemicals) (Unit: KRW trillion)

Korean Research-based Pharmaceutical Industry Association Korean Research-based Pharmaceutical Industry Association 4 2017 KRPIA Annual Report 2017 KRPIA Annual Report 5 KRPIA 7 2017 KRPIA2017 Annual Report A Leader in Innovative Innovative in A Leader Drug Development New Research-basedKorean Pharmaceutical Industry Association to contributes promoting health and advancing the pharmaceutical industry through the development, production, and supply innovative of new drugs. Korean Research-based Pharmaceutical Industry Association 2017 KRPIA2017 Annual Report 6 KRPIA 9 of Healthcare Policies R&M Committee R&M RA/IPR Committee of the pharmaceutical industry Research and Development Market Access Committee · Conduct policy research on the 2017 KRPIA2017 Annual Report Healthcare Policy Committee pharmaceutical industrypharmaceutical PA·Communications Committee PA·Communications socio-economic value of new drugs Ethical Business Practice Committee harmonized policy framework · Conduct policy research and cooperate with the government the for development · Analyze approval related policy Cooperation for Approval·IPR issues and suggestions establish to · Provide information on issues in the PA and CommunicationPA Activities for timelyfor reimbursement of new drug pharmaceutical industry and new drugs · Conduct activities raising for the value of the · Conduct policy research and make suggestions Chairman CEO of KRPIACEO KRPIA Activity General Assembly General Board of Directors 02. Stimulating R&D Activities Guidance for Ethical Management Ethical for Guidance pharmaceutical environment pharmaceutical suggestions focused on R&D committee · Conduct policy research and make · Conduct surveys on annual demand R&D for · Build a transparent and ethical · Support the operation of a code review KRPIA Introduction 01. Improving Patient Access Drugs to market access and reflecting the value of new drugs agencies drug for pricing systems and reimbursement policies Organization Major Activities · Develop policies improving for · Cooperate with government - Vision Mission Objective partner in placing top priority on patients KRPIA Activity 02. Developing New Drugs New Developing based on the highest drug capabilities R&D and information KRPIA will support the development of innovative drugs and their rapid supply KRPIA will establish ethical business practice in the pharmaceutical industry KRPIA will raise contribution of the pharmaceutical industry the to national health improvement KRPIA will provide the most up-to-date information on drugs the value of innovative new drugs is recognized as a responsible Provide the best treatment rapidlyand properly patients to in Korea Contribute the to healthcare and medical industries in Korea, in which 01 02 03 04 continuous R&D will enhance the public’s quality life of public’s the will enhance R&D continuous The Creation of Hope and Happiness by Happiness and Hope of Creation The The innovative new drugs that are produced and provided through through provided and produced are drugs that new innovative The KRPIA Introduction 2017 KRPIA2017 Annual Report 01. 8 Korean Research-based Pharmaceutical Industry Association(KRPIA) represents all its member pharmaceutical compa pharmaceutical memberits all represents Industry Association(KRPIA) Pharmaceutical Research-based Korean niesthat produce innovative newresearch-orientedpharmaceuticalglobal drugsand local where environment an create through strivingto is KRPIA lives. their continuous of quality R&D activities to enhancepatients’ healthcompanies actively invest in developing new drugs and contribute enhancing and to the health all of humankind. to enrich the KRPIA was established in March 1999 and gained official approval for an incorporated Healthassociation and in Welfare(MOHW) June 2000 and the by Ministry by Food of andthe Drug in 2014. Safety(MFDS) Ministry of As 2016, of its membership includes 40 a total research-oriented pharmaceutical companies.

KRPIA KRPIA - 11 •Right time •Right •Right dose •Right •Right route •Right •Right patient •Right •Right medicine •Right 5-Rights of Drug Adherence 2017 KRPIA2017 Annual Report KPAC •R&D Open Innovation•R&D •Collaboration in Overseas Markets Korea Pharma Association Conference •Development of the•Development pharmaceutical industry •Sharing R&D trends in an up-to-date•Sharing manner •Promotion of national•Promotion health via drug repositioning Street campaign KRPIA Activity Rak Mobile & Yak App. 02. prescription drugs by patients etc. compliance by diseases Mutual Growth through Open Innovation through Growth Mutual The LargestConference Global for Partnership in Korea, Korea Pharma Association Conference(KPAC) KRPIA2014, Since andKPBMAthe held Pharmthe‘Koreahave Association Conference,’ first privately led international whichconference the goal of creating an R&D ecosystem operative make to communication ending Open up R&D Innovation. Since Since 2011, KRPIA has conducted theCampaign Rak & Yak with KAPO(Korea Alliance of com drug significance of the improve and information provide to Organization) Patients pliance as a year-round campaign. It is supported by the MOHW(Ministry of Health and Welfare), KMA(Korean Medical Association), KPA(Korean Pharmaceutical Association), Hospital Nurses and Association), KHA(Korean KNA(Korean Association). ‘Rak & Yak Campaign’ for Improving Drug Adherence Drug Improving for Campaign’ & Yak ‘Rak •Development of education•Development materials for patients on drug of a mobile•Development application for drug compliance publicity activities •Public of healthcare•Education professionals activities:•Research Survey on the use of KRPIA Introduction 01. - - KRPIA Activity 02. industryand the improvement national of health implementing by orsupporting clinical It devised the code to ensure fair competition in distributing drugs among its member policies(2009) development(2012) drugs, protect patients’ rights, and contribute the development to the of healthcare and patient access(2014/2016) Ethical Management for a Fair Market Environment Market a Fair for Management Ethical Policy Research for the Future of the the of Future the for Research Policy Industry Korea in Pharmaceutical companies, maintain and to health improve the public’s controlling by monopolies, tradeand eliminate unfair as to wellas unlawful any practices lure customers. to activities in compliance with scientific and ethical requirements and procedures. code(2009, 2013) Major Research Papers KRPIA is committed to improving transparency in the pharmaceutical industry by estab search, it is in constant communication with the government, as a policy partner for the pharmaceutical industry, to properly establish policies for the pharmaceutical industry and healthcare industry. lishing and implementing rigorous ethical criteria ensure a healthy to society. KRPIA continuously conducts policy research to seek the direction development of the of sustainablethe pharmaceutical industry in Korea. Based on the results of its re The guidelines are designed to help member companies provide exact information on *IFPMA: International Federation of Pharmaceutical Manufacturers Association of Pharmaceutical Manufacturers Federation *IFPMA: International ·Publication of the ‘Green Book,’ an explanation·Publication of manual the ‘Green of the Book,’ fair competition ·Enactment of guideline(2014) Venue ·Enactment of the fair competition code(2002) ·Enactment of KRPIA guidelines on clinical activities(2007) ·Joined the IFPMA·Joined as a member(2007) •Improvement measures drug of price policies improved•Improvement for pharmaceutical industry on the comparison drug of prices•Research in OECD countries(2014) value enhanced of health and extended•Economic lifespan through new drug the of impact pharmaceutical of price regulation•Analysis investment(2011) on R&D taxbenefit clinical for trials report(2010) •World impact the of industry on BT R&D •Economic and its policies(2010) NHI of finance and•Outlook policy issues(2010) activities(2009~2014) on R&D •Survey the ethical management•Expanding the of pharmaceutical industry and research on KRPIA Introduction 2017 KRPIA2017 Annual Report 01. 10

KRPIA Value of New Medicine 13 2017 KRPIA2017 Annual Report Healthy Cycle of Innovative of Cycle Healthy Drug New Innovative new drug prolongs betterslife, quality and medical life of reduces total cost. The pharmaceutical industry quality creates jobs and highly added value as a new driving force Industrial theof 4th Revolution. Korean Research-based Pharmaceutical Industry Association 2017 KRPIA2017 Annual Report 12

Value of New Medicine Value of New Medicine - - - 15 2017 KRPIA2017 Annual Report ” The patients have the same expectations and concerns. Pa the words, other In well. workdrugs new the if happy feel tients efficacy of new drugs means quality of life for patients. New drugs are a whole new world. They will open up a new path activetoward lives patients for withhigh efficacy. effectiveHowever, treatment may remain a in ‘pie the sky’ if it is not the covered by NHI. Therefore, considering new drugs give patients hope, must they have better accessibility to the new drugs.able diseases, Isuch expectas rheumatism, incurwill be defeated one day whennew drugs become So,available. hopeI pharmaceutical companies will continue to accelerate the development of in novative new drugs. Lee In-ok | Penguin Korea We listen We patients to about possible high prices and lowabouthigh efficacy.” prices possible improve our health, while also making our concerned us improve also health, while “New Drugs Have Both Have Drugs “New and Concern’! ‘Expectation “New drugs the give us “New expectation that they will - - - - Cirrhosis of the liver and liver cancer are major causes of death of causesmajor are cancer liver and liver the Cirrhosis of in Korea. whileHowever, the high-risk groups in patients with alcoholics, to limited predominantly is C or B Hepatitis chronic the level of danger for these high-risk groups is incompara bly higher than for lung cancer or gastric cancer patients. In addition, as the death rate of liver cancer patients in the age brackets of 40s and 50s, when economic activitiesmost active, is higher than arethat of patients with other the cancers or diseases, the social burden the of diseases is much higher. In this situation, new drugs significantly reduce the potential the During cirrhosis. or cancer liver to Hepatitis of progression past 10 years, the 5-year survival rate of liver cancer patients increased by 2.5 times, and the death rate of patients with cir rhosis of the liver was reduced by Mosthalf. Hepatitis patients are now expecting to completely cure the disease as break through new drugs for chronic Hepatitis B were launched in chron treatcompletely can drugsthat new1990sand late the ic Hepatitis C began to be commercialized in the mid-2000s andwill be launched soon. Korea in Without these new drugs, patients could have suffered from the inability to treat Patients conditions. their by their aggravated feeling while diseases with chronic Hepatitis B or C will have virtually no difficulty in conducting daily activities when under treatment. This is how new drugs help Hepatitis patients lead ordinary lives. Itself!” Yun Gu-hyeonYun | Liver Korea 2017 KRPIA2017 Annual Report We listen We patients to My life has been entirely changed.” been entirely has life My and enjoy an active social life. an social active and enjoy get married, eat delicious food, play sports, food, play delicious eat get married, ‘Life’ “The New Drug Is New Drug “The 14 “Thanks to new drugs, I have been able“Thanks to get a job,

Value of New Medicine Value of New Medicine ------17 ” 2017 KRPIA2017 Annual Report line of hope for patients, and it gives them new life. In contrast, In life. new them gives it patients,and for hope of line new drugs can also be a ‘mirage.’ Though a new drug is avail it price, highits to patientspracticallyduecannot ifit useable, importantdrugsare newfor reasonthat Theillusion. an only is most patients is because eitheras completeparticular, In extendinglife. in critical factor a are they or ble treatment is impossi mainlysurgery andwith treated be cannotcancersblood most rely on anti-cancer therapies and drug treatments, new drugs hopethemgives these it patients especiallyas are valuablefor a complete cure. for New drugs are also great news to existingadversehelpsdrugs.reactions This hopeless to to due those patients who are them use the new drugs with an affirmative attitude and the expectation of being ‘cured,’ and brings better treatment re sults. Also, the development of new drugs are very important for blood cancer patients and their families as they improve their quality of life. But, for patients with financial difficulties, new drugs are a hope and a torture, and sometimes they ac difficul financial to due patients of lives the impoverish tually ties even though they use the drugs. I hope that new drugs will give those patients who are on the edge between life and deathsecond a chance living. at In a positive light, new drugs are a ‘lifeline.’ The availability of a availability of The ‘lifeline.’ a drugsare new light, positive a In new drug in a situation where treatment is impossible is a life but also a ‘Mirage’! also but | Korea Blood Cancer Association Pak Jeong-sook Pak We listen We patients to because they provide the possibility of a complete of recovery.” theybecause the provide possibility medicines, thus, newmedicines, drugs are more even important to them It is mostly impossible for leukemia to impossible receive patients mostly is It surgical operations. They are typically only treated only with are They typically surgical operations. “The New Drug Is New Drug “The a ‘Lifeline,’ Not Only “New drugs are essential to prolong patients’ lives. to drugs patients’ prolong are essential “New - - - - - In the past, when no treatment was available, patients hemophilia with could neither be vaccinated nor even sur simple have for lives their their risk to had they and extracted, teeth also hemophiliabut withpatients only not operations.So,gical their entire families suffered difficulties. The fact that the new drugs were created made patients’ lives better, even though basic treatment was another issue. It was inthe early ‘90s when hemophilia patients started ment. The to drugsget treat being used at that time were rived plasma-de treatments, which could accidently infect some patients developed,weredrugs newWhen HIV. HCVor viruses with like there were less problems than with ments. Medicines plasma-derived that are treat half-life extended and new drugs with gene therapy enable hemophilia patients to live active lives. Therefore, the development of more safe and effective new drugs is essential the patients. to Drugs build the hope of a healthy physical condition and fu necessaryalsopatients.aresense,they thisfor Inture their for families. It is necessary to have an active supply of new drugs the patientsfor with diseases rare whose only hope the is new drugs. ” 2017 KRPIA2017 Annual Report Kim Dong-kwan | Korea Hemophilia Association We listen We patients to patients’ only hope and life itself. Their lives were at risk risk at were lives Their hope only itself. and life patients’ old days if new daysold drugs if had not been invented.” even for simple surgery. We would still be living like in the in like be living would still We for surgery. simple even 16 ‘Quality of Life’! of ‘Quality “The New Drug Is New Drug “The “Before there was medicine, there treatments was “Before hemophilia were

Value of New Medicine Value of New Medicine - 19 2017 KRPIA2017 Annual Report !” As a single flap of a butterfly’s wings on an island in the Phil- Florida,reach will hurricanestrongthat a generate canippines new drugs have a tremendous effect not only on the patient suffering from a disease but also on all who are involved with the patient such as his/her family members and friends. of duration thedecrease and lives patients’prolong drugs New of lack the to due die to waiting are patientswho for treatment proper medicines. For the patients undergoing urgent health rea that For speak, lifeline. a to so drugs new are, conditions, son, new drug development is important and much needed. Patients who are terminally ill without new drugs spend most of their time either in a coma in the ICU or frequently visiting the ER with pains and fears. Patients who are provided with new drugs can spend their precious time at home with their families, not on cold hospital beds. We listen We patients to Ahn Ki-jong | Korea Alliance of Patients Organization “The New Drug Is New Drug “The Effect’ Butterfly ‘the that the patients will live with.” live that the will patients suffer from diseases. New drugs have actually a diseases. from suffer and the on their people families impact significant “New drugs are treating not only “New the who patients - - - ” ier and will eventually be able to lead healthier lives. Such small patients,alsobut of qualitylife theonly of changesnot enhance supply developmentand the believe I families. entire their of that econo national the to contribute significantly will drugs new of asmy patients with rare diseases can work go to without losing labor power. All stakeholders need to make ef forts expand to the NHI coverage these for drugs. Like Like an oasis in the desert, new drugs are a driving of force life. Even though new drugs do not benefit all patients, the - availa bility of a new drug brings momentum patients to hopehave to with a desire for life. Unlike for those with other diseases, new patientsdesperatelyneeded for are andhope only the are drugs with rare diseases. Therefore, even if they cannot immediately use the new drugs because of a lack of money, have the hope patients of using the cannew drug in the future after saving enough money. For patients with rare diseases, new drugs are the sole hope, even a desperate one. Most patients with rare diseases suffer from internal disabilities such as complications. The lives of patients will become much better with the availability of drugs that can curb the aggrava- tions diseases of and slightly improve symptoms, in addition to treatment. I remember once stiff girl’s a hands turned soft after taking newa drug(injection), and now, though clumsy, she can play the piano, making me weep while grabbing her hands. When the development symptomspatients,theimprove drugs of new supply helps to of and carryactivities,morebecome healthoutto willthem they allow ‘Oasis in the Desert’! ‘Oasis 2017 KRPIA2017 Annual Report We listen We patients to with rare diseases to go go to to school, and work, live diseases with rare their ordinary lives. Patients are all willing to sell willing are all Patients their ordinary lives. theretheir a new drug.” if house is an “The New Drug Is New Drug “The 18 “The development of new development of drugs many allows patients “The Shin Hyeon-min | Korean Organization Rare for Diseases

Value of New Medicine Value of New Medicine - - 21 03 2017 KRPIA2017 Annual Report Increase in Increase IndustryInvestment 05 Stimulation of R&D 01 Enhancement of Enhancement People’s HealthPeople’s & Happiness 04 through Beating Diseases Beating through 02 & Increase Supply Increase & Develop New Drugs Development of the Pharmaceutical Industry Pharmaceutical Realization of an Ecosystem for a Healthy Society a Healthy for Ecosystem an of Realization New drug development prolongs patients’ lives and helps them realize their dreams. Innovative new drugs are the prod the are drugsnew Innovativedreams. their realize them helps and lives developmentprolongspatients’drug New developed,diseasesbeingdrugs new innovative these to thanksefforts,andconstant pharmaceuticalcompanies’ of uct that are known to be incurable, such as leukemia and AIDS, are developmentnow the becominginvigorate manageable,to imperative showingis drugs newrelatively of equal value the diseases.Recognizing chronic of those as rates death and supply new of drugs trillion development. that require for years 10~15 and The KRW recognition 1~2 the of value of new drugs allows companies to develop and supply more new drugs by vancing the pharmaceuticalenhancing industry. This thentheir leads to promoting R&D the health andinvestments happiness of the people.and This is the ad ‘Healthy Ecosystem’ created the by development new of drugs. now more than ever! than more now with good health and happiness, and health good with In the era of the 100-year lifespan 100-year the of era the In are essential are drugs new innovative the pharmaceutical industry provides a healthy and happy life through drugs. In this era of the 100-year lifespan, when people live longer even with diseases, provide innovative new treatments and their rapid distribution patients to and their families. 2017 KRPIA2017 Annual Report KRPIA and the global pharmaceutical companies have never stopped developing new drugs in order to 20

Value of New Medicine Value of New Medicine - 23 Generation . 5 95-96 2014-2015 4th Mixed treatment with oral therapy

Generation 90 2013-2014 + IFN injection 3rd Polymerase inhibitors 01 2017 KRPIA2017 Annual Report of patients diagnosed with head Generation 63-80 2011-2013 + IFN injection 2nd of female workers diagnosed with breast cancer Protease inhibitors of cancer diagnosed patients returned to Cure rate of hepatitis C(%) 81% France: 82% Japan: The Netherlands: 83% Generation

41 injection 3 2 1 New driving the of force Interferon & returned to their workplaces after 10.8 months of sick leave workplaces within months 12 after their first day of sick leave and neck cancer returned to their workplaces, and mostly they returned in about 6 month after treatment 1999-2010 1st ribavirin(IFN-R) ribavirin(IFN-R) 03. 4th Industrial Revolution Due to a new drug development, one of major incurable dis eases, hepatitis C had its cure rate increase up hepatitisyearsonlyof was20 beforerate to thecureC ago,Even by 133%. reachesup rate the treatment,now but of year a for about41% two for 96% to three 95% to to months of treatment Value of New Medicine New of Value . - - - 6 South South Korea 19 [KRPIA] New drug saves lives and improves quality life of , which also 12 3 Australia Japan 26 Effect of ‘Total Medical Effect ‘Total of 02. Cost Reduction’ . 5 European countries 7 even after being diagnosed with cancer with being diagnosed after even 23 . 4 US 27 Mexico Canada 18 Rate of decrease of cancer death rate(%) 23 ‘Life Prolonging’ and With innovative treatment, cancer patient could return to their workplace their to return could patient cancer treatment, innovative With 01. Improving Quality Life of Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982-2001 Countries, 52 from Data Disease-Level Longitudinal, Evidence from with New Drug Development return to work in head and neck cancer survivors,” Oral Oncology Oral work in head and neck cancer survivors,” to return “Factors related to return to work by women with breast cancer in Northern France,” Journal of Occupational Rehabilitation; Verdonck-de Leeuw, 2010, “Employment and “Employment 2010, Leeuw, Verdonck-de Journal of Occupational Rehabilitation; cancer in Northern France,” women with breast by work to return to related “Factors resulted in two out of three cancer patients manifesting mini mum five-year survival rate After 1991, when the death rate by cancer reached the peak worldwide, launching of new anti cancer treatment contrib uted to significantly dropping death rate by 25% According According to cases from Japan, France and the Nether lands, about 80% of cancer patients were able to return theirto workplace within a year 1. The Impact of New Drug Launches on Longevity: on Longevity: Impact of New Drug Launches 1. The of Life and Life extension Economic Value 2012. Yung. Kwan & Jeon Gyeh 2. Ryu Keun NCI 3. ACS, Center 4. American Cancer Society Cancer Statistics industry profile Biopharmaceutical research against hepatitis C; PhRMA, 2015, of progress 25 years 5. PhRMA, 2014, epidemiology,” Occupational Medicine and employment: “Cancer survivorship 2009, 6. Amir and Brocky, 2010, Fantoni, cancer: a 365-day cohort Journal of Cancer Survivorship; due to study of Japanese cancer survivors,” sick leave work after to “Returning 7. Endo et al., 2015, Four out of five cancer patients worldwide were able to return to their workplaces even after being with diagnosed cancer due to innovative anti cancer treatment . - - 2 1% trillion worth of Social Value Social 126 About KRW national social value created at most expectancy by innovative new drug By reducing death rate of Social economical benefit of prolonging life New driving the of force 03. 4th Industrial Revolution Extension of life through innovative new drugs delivers significant socio-economic benefits society. to The value to an entire nation when the death rate is reduced by 1% is estimated to amount to a maximum of approximately KRW 126 trillion. The economic value increase in Korea experienced due tothe decrease inthe mortality rate be tween 1990 and 2010 is estimated to be betweenbe approx estimatedto is 2010tween and1990 imately KRW 940.2803 trillion andKRW 2325.1542 trillion year 1.96 2000 0.79 1.82 1999 0.74 1.65 1998 0.70 1.53 1997 0.66 1.37 1996 0.62 1.21 Effect of ‘Total Medical Effect ‘Total of 1995 0.60 1.07 02. Cost Reduction’ 1994 0.56 0.94 1993 0.51 0.76 It is the age of new drug could cure diseases cure drug could new age of is the It 1992 0.45 which took countless lives without the right cure right the without lives countless took which 0.70 1991 0.38 . 1 0.57 1990 0.30 ※ International Journal of Health Care Finance and Economics 0.37 1989 0.21 prolonging life expectancy 0.23 Prolonged years of life after launch of NCE Total prolonged years of life expectancy 1988 0.12 ‘Life Prolonging’ and Prolonging’ ‘Life 0.06 1987 The effect of launching of new drug on

1986 ‘Life Prolonging’ and 2017 KRPIA2017 Annual Report 2.50 2.00 1.50 1.00 0.50 0.00 years 01. Improving Quality Life of Number of New drug, contributing on patients worldwide on patients drug,New contributing to live longer, healthier and more productive life productive more and healthier longer, live to 22 Pharmaceutical R&D has dramatically improved the lives patientsreduced of aswell as death rates.The study said that the average life expectancy increased by 1.96 after NCE. And the result covers 52 nations including Korea and US, from 1986 to 2000. It could be concluded that new drug launches accounted for 13% of the 1986-2000 increase in longevity 01. Improving Quality Life of Improving

Value of New Medicine Value of New Medicine - . 25 13 2 Germany EUR 22 billion 22 EUR 2017 KRPIA2017 Annual Report by developing new drug stopping development of Parkinson’s disease Estimated amount be to saveduntil 2040 New driving the of force . In Germany, if a new drug to stop advancement of 12 The UK 03. 4th Industrial Revolution tia of GBP 21.2 billion(KRW 31.33 trillion) for treating demen Parkinson’s Parkinson’s disease was developed, EUR 22 billion(KRW 28.74 trillion) and a new drug to delay advancement by 20%, couldtrillion) be saved billion(KRW 5.96 EUR 3.9 Value of New Medicine New of 0 Value for five years GBP 21.2 billion [KRPIA] New drug reduces medical cost Estimated amount be to saveduntil 2050 . As for the UK,the for As . by developing new drug delaying dementia 11 Effect of ‘Total Medical Effect ‘Total of 02. Cost Reduction’ Increased medical is inevitablecost aging of in era the society The US USD 376 billion USD 376 Alzheimer’s disease for five years by developing new drug delaying ‘Life Prolonging’ and Estimated amount be to saveduntil 2050 New drug medicalNew inflation be could future anof solution effective cost prevent to 01. Improving Quality Life of Research, Working Paper No. 8996. June 2007. Available at http://www.nber.org/papers/w8996.pdf. Available No. 8996. June 2007. Paper Working Research, 11/16/12 Accessed Health Economics 1995-2003,” 8. Lichtenberg FR. Benefits and Costs of Newer Drugs: An Update. National Bureau of Economic National Bureau of Newer Drugs: An Update. and Costs FR. Benefits 8. Lichtenberg countries, OECD on 20 data longitudinal country-level countries? Evidence from OECD in 20 hospitalizations newer CV drugs reduced “Have 2009, 9. Lichtenberg, BMC Public Health vaccination,” seasonal influenza “Annual public health and economic benefits of 2014, 10. Preaud, 11. Alzheimer’s Association action evidence and a vision for Defeat dementia: The UK, 2014, 12. Alzheimer’s Research Congress 15th Annual European ISPOR stages,” Yahr Hoehn and through disease in Germany: modeling progression of slowing Parkinson’s “Economic value 13. Johnson, 2012, In the US, total of USD 376 billion(KRW could 423.75 be trillion) saved until 2050 by developing new drug for yearsfive by diseaseAlzheimer’sdelaying a treatment to delay dementia for fivereduceyears could for dementia delay to treatment a 666,000, by patienttheresult number couldwhichthe of in decrease in number of caregiver by 566,000 and cost - . 9 89$ - HospitalizationCost Financial Value Financial person Cost per . 10 24$ Cost of new drug Cost-saving Effect by using adequate drugs Cardiovascular new drugs resulted in hospitalization New driving the of force cost reduction in 20 OECD members(from 1995 to 2004) 03. 4th Industrial Revolution Due to new drugs, 20 OECD medicalrelated diseasecardiovascular member of 70% saved have countries could cost. By spending USD 24(KRW 27,000) on new cardio vasculardrug, thepatientabout savecould 89(KRW USD 100,000) shorter from period hospitalization of Meanwhile, Europe prevents patient’s hospital visit and influenza seasonal providing by leave sick and admission vaccination, which saves about EUR 220 million to EUR 3302.87million(KRW trillion KRW 4.31 to worth trillion) of medical cost a year - 7$ - Effect of ‘Total Medical Effect ‘Total of cost by 02. Cost Reduction’ Reducing medical medical Reducing the people and government’s financial burden financial peoplethe government’s and innovative new drug 1$ + Adequate use of pharmaceuticals would significantly reduce significantly would pharmaceuticals of use Adequate . 8 Effect of ‘Total Medical ‘Total of Effect Investing on new drug by ‘Life Prolonging’ and 2017 KRPIA2017 Annual Report 01. Improving Quality Life of Contributing reducing to medical cost by investing on New drug reduces total cost of our society our of cost total drug reduces New system sustainability NHI of improves and Cost Reduction’ 24 02. Use of new drug directly affects reduction cost. When of prescribing a medical new drug, the pharmaceutical existingdrug, to compared 18 USD increaseby could cost but the total medical cost(including outpatient and in patient diagnosis, home care, emergency room fee) of USD could111 be saved. In other words, by investing USD USD save could onedrug, new innovative for 1,125) 1(KRW or 7(KRW more7,900) for using cost-efficient drugs and care disease

Value of New Medicine Value of New Medicine 27 3.6 2016 3.9 71.7 11.5% 3.3 2015 (From 2005(From 2015) to Pharmaceutical Pharmaceutical manufacturing industry manufacturing Pharmaceutical industry Pharmaceutical 2.5 2014 2017 KRPIA2017 Annual Report (unit: KRW trillion) (unit: 2.3 2013 2.6 Annual average growth of 33.7 General General industry Average in general Expert employment rate is higher than double 2.3 New driving the of force 2012 manufacturing industry manufacturing Annual average increase of employment(%) of increase average Annual Pharmaceutical export performance by year 03. 4th Industrial Revolution Ratio of Master’s and Doctoral degree among researchers(%) - - - - - . 16 . Moreover, Moreover, . 45.5 15 industry manufacturing manufacturing Pharmaceutical Pharmaceutical and leads economical growth leads economical and (From 2009(From 2014) to 40.0 industry Effect of ‘Total Medical Effect ‘Total of Air transportation 02. Cost Reduction’ 36.8 R&D industry Pharmaceutical industry generates quality industry jobs generates Pharmaceutical The pharmaceutical industry leverages overseas export overseas industry leverages pharmaceutical The 27.6 industry Manufacturing Manufacturing 23.4 industry Computing Computing ‘Life Prolonging’ and 01. Improving Quality Life of Youth employmentYouth increase rate by industry(%) 14. Ministry of Food and Drug Safety, Korea Pharmaceutical Traders Association Pharmaceutical Traders and Drug Safety, Korea 14. Ministry of Food Industry. on Mining and Manufacturing Report Research Office(2012). National Statistical 15. Korea and Planning, 2014) of S&T Evaluation Institute Report.(Korea Activity 16. Research Through global market expansion of Korean export ceuticals,pharmaceuticalstotal the volumeof was pharma increasedannually11.5% by lastin five years to 2012 from 2016.Especially theexport volumebio pharmaceutical of year significantlyperincreased years five last products for by 30.7%. Increasing export volume by 34.8% compared to the year before, bio pharmaceutical products has significant growth a potential in the future and is expect ed to lead Korean economic growth as next generation driving force. Recognizing such potential, industrygovernmentincludedpharmaceuticalbio andas the Korean ‘high value generating future emerging industry devel- opment plan’ of the 100 andAffair State Tasks, promised institutional support the industry. for According to employmenttry, 5,400 to 6,100 jobs were generated per indexKRW 1 trillion of pharmaceutical of sales revenue, and to indusdevelop four blockbuster-level new drugs, about 150,000 to 170,000 jobs would be gen erated. Also according to data analysis by the Statistics Korea, amount of value added per person in ceutical pharmaindustry is about KRW 270 million, which is KRW 100 million more than a general manufacturing industry, andexceeded that of the electronics industry pharmaceutical industry has ratiodoublyresearchersdegree71.7%,is amongwhichall al of of master’s and doctor- higher than 33.7% general of manufacturing industry - . 14 12.9% trillion Year 2016Year 21.73 KRW Industrial Value Industrial trillion 19.24 Year 2015Year Size of Korean pharmaceutical industry KRW New driving the of force Increased growth rate compared last to year: 03. 4th Industrial Revolution volume of KRW 1.20 quadrillion. Such volume is double or triples the volume of automobile and semi-conductor industry. The volume of Korean pharmaceutical market has surpassed KRW 20 trillion in 2016 due to launch of global new drug and impressive performance of export ing technology. The figure in 2016 recorded growth of compared the figure to 12.9% the from year before - 1.2 industry KRW quadrillion quadrillion Pharmaceutical Pharmaceutical Effect of ‘Total Medical Effect ‘Total of

02. Cost Reduction’ to lead the Fourth Revolution the Industrial lead to 600 trillion industry KRW Automobile Automobile The pharmaceutical industry driving is a new force pharmaceutical The

400 New driving force of the 4th 4th the of force driving New Size of global pharmaceutical industry trillion industry ‘Life Prolonging’ and 2017 KRPIA2017 Annual Report KRW 01. Improving Quality Life of Semi-conductor Semi-conductor The pharmaceutical industry is future driving within force the Fourth Industrial Revolution era. By developing new drugs, the industry leverageseconomic Korean growth expands high value added and R&D quality creates jobs. Industrial Revolution 26 The pharmaceutical industry is not only the collection of technology based on the Fourth Industrial but Revolution, also reviewed as a future growth engine higher to value create by generating quality jobs and innovation. The world pharmaceutical market is sustaining annual average of 5.2% growth with economic growth and in creased medical demand, which currently reached total 03.

Value of New Medicine Social Contribution 29 2017 KRPIA2017 Annual Report Happy PartnerHappy Tomorrow for Healthy KRPIA and global pharmaceutical companies various promote social contribution activities and grow be to happy society together with Korean Korean Research-based Pharmaceutical Industry Association 2017 KRPIA2017 Annual Report 28

Social Contribution Social Contribution - - - 31 45% drugs CSR Activities in Korea 04. New 2017 KRPIA2017 Annual Report 45% OECD Sustainable Compared with average price of OECD members OECD of price with average Compared lent drugs is the mission and primary value of pharma in companies, pharmaceutical Global companies. ceutical particular, are taking the initiative in supplying drugs for treating severe diseases, such as cancers, rare diseases, and chronic diseases, be which yet defeated. to have peared be the to lowest among OECD countries. We lead the industry the lead in developing We supplying drugsand for new diseases! defeating excel providing by diseases from humankind Protecting Patients of Improvement Drugs New to Accessibility Since Korea adopted the positive listing system in 2007, the prices new of represent drugs as low as 45% Korea in of the average price of OECD members. Moreover, the prices of 73% of the new drugs listed for the NHI ap New Prescription to Access Patient Improving for : Proposals ※Source 2016 Pharmaceuticals in Korea, 03. Management - - - Partnership and 02. Collaboration 1,200 about Total supplied drugs supplied Total Drug Development

Drug Development 01. and Supply 01. Drugs Supply of In Korea, global pharmaceutical companies are supply ing about 1,200 different drugs needed by patients. particular, In they are supplying mainly ETC drugs, lives, patients’ which of extension the connectedwith closely are and original drugs for treating diseases such as rare dis eases whose treatments were not available in the past. In addition, they are also taking the lead in developing and supplying for vaccines diseases preventing and protect ing health. and Supply 02 04 Collaboration CSRActivities Partnership and Partnership Every Day, Companies Build Companies Day, Every 01 03 collaborating with local pharmaceutical companies, and cultivating human resources. and Supply Sustainable Sustainable Management 2017 KRPIA2017 Annual Report happiness circulates by starting with the supply of excellent drugs and providing direct support to patients and underprivileged people, strengthening global competitiveness synergistically in R&D, Global pharmaceutical companies actively participate in building a sustainable environment where a Happier Korea Where Happiness Circulates! Happiness Where Korea a Happier Drug Development 30

사회적 기여 Social Contribution - - 33 CSR Activities 04. 2017 KRPIA2017 Annual Report Cases Sustainable 03. Management Korea(located in Songdo, Incheon)(collaboration with Samsung Biologics) bio·pharmaceutical industry. bio·pharmaceutical in major research institutions Drug Safety(MFDS) in Korea between 2008 and 2012 Bioneer, LegoChem Biosciences, PharmAbcine, etc.] Pneumococcal Conjugate Vaccine(PCV). This is the agreement including R&D and Innovation Drug Discovery Program jointly with research teams in Korea research(2008-present) production of innovative PCV(Collaboration with SK Chemicals) research institutionsresearch Open Lab foundation) [collaboration with SNU and KAIST] with the four major hospitals in Korea(Samsung Medical Seoul Center, National University, Center and ANRT] Global PS, a CRO in Korea use in conjunction with immuno-oncology therapies World(2010/2011, Ministry of Health and Welfare) and KHIDI expansion of academic exchange programs over the next 5 years(2014~2018) explore opportunities for technical cooperation and strengthen to partnerships with local graduate student gastric cancer and lung cancer genomic data from those patients [collaboration with Asan Medical Center] discover new drug for hepatitis B [collaboration with Institute Pasteur Korea] drug development with the clinical trial centers(SNUH, SMC, AMC, Sevrance Hospital) (R & D), contributed & D), (R domestic to new drug development and healthcare infrastructure (Korea, China, Japan, and Singapore) Asan Medical Yonsei Center, University) in 2012. - Conducting phase I clinical trial with candidate compounds of new drugsfor treating - Producing active pharmaceutical ingredients and finished drugs of BMS at a plant in - Collaborative research across the world and obtained 250 licenses in Asia(2007~2011) - Co-host the conference with the Korea Trade-Investment Promotion Agency(KOTRA) to •Pfizer Korea entered•Pfizer into INSPIRE‘s new partnership program for clinical trial cooperation •Conducted about 80 global clinical trials in 2016. R & D University:•Pfizer Medical R&D training program for university students and Symposium(Co-host•‘R&D with KoNECT) •Ranked 1st in Korea on•Ranked number of clinical trials and number of registered patients in the the•Recorded highest number of IND protocols approved by the Ministry of Food and MOU with•Signed Korea‘s Ministry of Health and Welfare for research and development •Partnership with Korea Drug Development Fund(KDDF) agreement•Research share to clinical data of liver cancer patients and produce to •Introduction of Global Post-Doctoral Program in Korea [collaboration with Asan Medical develop to •Agreement a new discovery platform for immune-oncology therapies research develop to antibiotic•Joint candidates eradicate to nosocomial infection and to •Establishment of the 'PREMIER NETWORK' a comprehensive networking program in new research on diseases•Joint prevalent among Asian people [collaboration with ANRT, long-term strategic•A cooperation for the co-development of an innovative •Co-development of Anti-ulcer Combination Drug •Collaboration with Dong-A-ST for MerTK inhibitors in pre-clinical development for drug•Anti-cancer research support program(KHIDI) •Conducting Asia‘s first comprehensive clinical study and pre-clinical study projects investigational•Supplying compounds oncology to researchers in 4 Asian countries research on mutations•Joint in lung cancer tissues Clinical•Master Agreement Trial with clinical trial institutions in Korea for producing•Agreement commercial bio antibody-based new drugs •Development of treatment for multi-drug resistant tuberculosis(sponsor Cantos GSK Tres •Pre-clinical study in new candidate compounds for anti-cancer drugs jointly with major First in Patient Trial •Start Study in new candidate compounds for new cancer-epigenetics Clinical•Master Agreement Trial with clinical trial institutions in Korea with MOHW:•MOU investing $80 million for R&D for severe and infectious diseases and with the•Agreement Korea Research Institute of Chemical Technology through the Open •Collaboration Academy with Seoul Bio Hub co-hosted by Seoul Metropolitan Government •Discovery of candidate compounds(collaboration with Biotech) •Partnership between CHORUS, a new drug research institution of Lilly Korea and LSK Ambassador‘•‘Science Global Partnering•KOTRA Conference(2017) Partnership and BMS BMS Pfizer Pfizer Korea 02. Collaboration Novartis Korea Ltd. Korea Ltd. Lilly Korea GSK Korea •CTC Bio •CTC Abott Korea Servier Korea sanofi-aventis Janssen Korea MSD Korea Ltd. Pharmaceutical Pharmaceutical Pharmaceuticals Pharmaceuticals Sanofi Pasteur Ltd. AbbVie•DongA ST AbbVie•DongA AstraZeneca Korea AstraZeneca Global pharmaceutical companies are conducting R&D programs for developing new drugs jointly with phar with jointly drugs new developing for programs R&D conducting are companies pharmaceutical Global maceutical companies, medical organizations and competitive global research and capabilities implementation research enhancing to institutionscontributing are companies global in Korea. Through these programs, ness of researchers in Korea. Drug Development 01. and Supply R&D Open R&D Innovation - - - - CSR Activities 04. Cases Sustainable Global pharmaceutical companies are making various ef various making are companies pharmaceutical Global forts to synergistically collaborate with local pharmaceu tical companies and organizations in Korea for the con tinued growth and development of the pharmaceutical industry this end,in Korea. theyTo are carrying out pro grams, such as R&D open innovation and cooperation, expandingfor overseas into markets. Global pharmaceutical companies companies Global pharmaceutical Korean with together growing are industry!pharmaceutical 03. Management Exclusive licensing agreement for Kanarb, ARB medicine for high blood pressure, in Southeast 13 Asian countries In discussions for overseas expansion of ‘Rovelito,‘ the Korea‘s first ARB- drug combination Statin A worldwide license agreement develop to a portfolio of experimental, long- acting diabetes treatments Licensing of diabetic treatment ‘Zemiglo‘ in about countries 70 License agreement for the 3 incrementally modified new drugs within Asia Co-promotion of ‘Tedizolid,‘ an antibiotic for super bacteria, in overseas markets(excluding America and Europe) Investment in shares Exclusive license and collaboration agreement for the development and commercialization of HM71224, treatment of autoimmune and other disease Collaboration agreement on technology export for co-development and commercialization of diabetes/obesity treatment Co-promotion of ‘Tedizolid,‘ an antibiotic for super bacteria, in overseas markets(America and Europe) Investment in a combined R&D of ‘Cozaar ,‘ XQ treatment for hypertension, and partnership for exporting it over to 50 countries Collaboration agreement for global commercialization of biosimilar products with Samsung Bioepis Collaboration with Genewel for licensing, distribution and promotion of Medifoam®, a moist wound dressing product Pharm Pharmaceutical Partnership and Sanofi•LG Chem Sanofi•LG MSD•Dong-A ST MSD•Dong-A Abott Korea•CTC Bio Abott Korea•CTC MSD•Samsung Bioepis MSD•Samsung 02. Collaboration Bayer Korea•Dong-A ST Bayer Korea•Dong-A sanofi-aventis Korea•Hanmi sanofi-aventis Korea•Hanmi MSD•Hanmi Pharmaceutical MSD•Hanmi Sanofi•Hanmi Pharmaceutical Sanofi•Hanmi Mundipharma Korea•Genewel Zuellig Pharma Korea•Boryung Janssen•Hanmi Pharmaceurtical Janssen•Hanmi Lilly Korea•Hanmi PharmaceuticalLilly Korea•Hanmi GSK Korea•Dong-A Socio HoldingsGSK Korea•Dong-A Global pharmaceutical companies are sharing their own experiences with in local the pharmaceutical global companies market by jointly expanding into overseas markets.these partnerships, global companies Through help local companies reduce setbacks and successfully branch out the global into market. Partnership and Drug Development 2017 KRPIA2017 Annual Report 01. and Supply Collaboration Marketing Marketing Collaboration in Overseas Markets 32 02.

Social Contribution Social Contribution - - - 35 CSR Activities 53% 04. Family 2017 KRPIA2017 Annual Report Children Health Individual Ratio of female board member Life Social BALANCE WORK LIFE WORK Deadlines Sustainable Sustainable 03. Management Success Goals Career Future Male 45% Female Ratio of female employee Partnership and 02. Collaboration In 2016 ly Korea, Roche Korea, MSD Korea, BMS Korea and other companies have been certified paternity leave, maternity leave, shortened work hours during infant care, flex time and remoteworking. With such effort, Abbott Korea, AbbVie Korea, sanofi-aventisKorea, Lil help them balance work and life. ily life better. To support employees managing work and family life of pregnancy, and of of about 45%. As such, global companies have shown high interest on training female the gender ratio of executive board members reached about 53% with HR and promo tion affairs keen on gender equality. KRPIA’s KRPIA’s global pharmaceutical member companies manifest female employment rate workers, and providing equal opportunity for them to reach their full potential. Especially, potential. full their reach opportunity to equalprovidingthem workers, and for child birth and care, the global companies have adopted various employee benefits like benefits like employee various adopted have companies global the care, birth and child as ‘Family-friendly Company’ by the Ministry of Gender Equality and AndFamily. many members to family their bring employees to the systemfor ‘familyday’ a offercompanies Global pharmaceutical companies are supporting employees to balance work and fam Drug Development 01. and Supply culture of culture equality Balance and gender Corporate Work & Life & Life Work Valuing diversity Valuing - - - CSR Activities 04. 8,679 | 2016) (in Sustainable Sustainable corporate culture with diversity! culture corporate agement to seek long-term mutual growth Specifically, the andglobal companies provide dream. opportunity for fullestexploresuperbcapabilitiestheiremployeestheir at to by creating quality jobs constantly. Companies also value diversity and gender equality, while they set examples creating corporate culture of work of and balance. life Global pharmaceutical company operates sustainable man sustainable operates company pharmaceutical Global Generating quality jobs and advanced Sustainable management based on 03. Management Employees Partnership and *Remarks: Figure based on number of employees reflecting organizational changes of member companies 02. Collaboration healthcare sector experts. rea. By providing opportunity for expert employees to explore their full potential, the of Korean healthcare Korean of sector. employees to understand and explore the industry better, and global field study pro experience and ideas, and global leader training program, letto the employees grow as gram for them to visit and experienceheadquartersthecompanies.andMeanwhile,global visit of to them for gram global companies provide diverse educational programs, such as training program with Many of global pharmaceutical companies are offering internship to let future potential companies contribute training outstanding human resources needed for development cooperation with a medical college, lecture program sharing various knowledge and Global pharmaceutical companies with KRPIA are generating total of 8,679 jobs in Ko Sustainable Sustainable Drug Development 2017 KRPIA2017 Annual Report 01. and Supply 03. resources 34 Developing Developing Generating jobs Generating with added high with Management future human future value

Social Contribution Social Contribution 37 group Operating internal volunteer CSR Activities 04. science 2017 KRPIA2017 Annual Report Developing Developing medicine and Donation Sustainable 03. Management 02. Partnership and Collaboration to beto a partner of the Korean society advancing forward. Global Pharmaceutical Company Global Pharmaceutical Corporate Social Responsibility of of Responsibility Social Corporate and youth With various types of CSR activities, KRPIA and member companies would strive Contributing to local community Supporting child but also they value giving back the to Korean society as a member of the community. Drug Development patient 01. and Supply Supporting Supporting Global companies not only carry the duty of supplying innovative new drug as a pharmaceutical company, - - (2016) 0.47% CSR Activities 27 companies 04. Globalpharmaceutical times higher

total markettotal value the top 100 companies by Sustainable 2.5 in Korea are making contributions to Korean society in including donation activities, support for patients and un ingful contributions to orean society through the active people’s health. people’s participation and interest of employees, beyond providing monetary simply support. In addition, they have been various ways. They are conducting a variety of programs support for promoting science, and the improvement of continuously conducting various CSR activities for over derprivileged people, support for regional communities, 10~15 years,10~15 not just holding onetime events. As corporate citizens, global pharmaceutical companies a diverse range of people! of range a diverse We support happiness of the We These are all efforts to make more significant and mean 03. Management than (2015) 0.19% companies The average of 255 average The 02. Partnership and Collaboration Global pharmaceutical companies are returning a part their of profits the society. to companies27 KRPIA of billion, donated which KRW their of 24.7 is 0.47% whole income. CSR Activities Drug Development 2017 KRPIA2017 Annual Report 01. and Supply 04. Charitable Contribution 36

Social Contribution Social Contribution 39 CSR Activities 04. 2017 KRPIA2017 Annual Report Major Activities Major Sustainable breast cancer, gastrointestinal stromal tumor, etc. patients who suffer from rare disease pediatric cancer patients and their family on the company foundation day Myelodysplastic Syndrome understand disease and how to treat Korea by adding a matching grant of Lilly Korea. volunteered for the disabled and facilities tests due to financialdifficulties, with Korea Association of Medical Social Workers standing assistance devices. society mom and patient who suffer from lupus erythematosus. mom of Good Neighbors’ Good Heart Center in June. rate rehabilitation facility for patients with mental disorders) employees shared low-salt breakfasts and participated in donation in celebrationof World Cancer Prevention Month. or chronic diseases to provide emotional and psychological care earn donation points and donate this point to single moms. diseases and donate money to charity) disease patients, a new campaign that began with ‘Pit-A-Pat Bucket Challenge’ in disease disabilities, and delivering them to hospitals and treatment center therapists disabled in National Rehabilitation Center diseases to provide emotional and psychological care donated to ‘Korea Lupus support group’ in Oct. 3million KRW were deposited and donated to the project to support the single 2015 and ‘Hopeful Sprouting Campaign’ in 2016 7,000 known rarediseases worldwide(increase the public’s awareness of such •On 4th November,•On 2016, we visitedthe local Holt Child Welfare Foundation and •Supported 65 million won •Supported for program to make patients and families with Multiple Myeloma & •Cover diagnosis•Cover expense for low-income patients who cannot afford diagnostic •To promote the prevention•To and social attention of gastric cancer, Lilly Korea’s funds were delivered•The to the Social Welfare Organization Community Chest of •Donate for a local•Donate Senior Care Centre to support the patients who need the •CSR program•CSR that involves employees and HCPs to support patients with over •Donation to improve treatment environments for patients with childhood cancer, video experiences•VR by the public for funds to be donated to pediatric heart •Emotional support program for breast cancer patients who are suffering from •Arts & culture•Arts programs for child-patients, their sibling and caregivers with rare •Aims at early•Aims discovery of infectees, early treatment and reduction of infection •Make a Wish Bear•Make with 'MAKE A WISH' Foundation which cheers up pediatric meet•Athletic with mental disabilities who are struggling for rehabilitation •Making Maracas, a therapeutic tool that can stimulate the senses of children with •Help patients•Help with schizophrenia to overcome social prejudice and return to •Execute volunteering with 'SROLANH' and ‘Taiwha Fountain House’(vocational •Participate 'Experience program for awareness improvement of disability' with to'Healing •Go picnic' with disabled in National Rehabilitation Center •Patronize society•Patronize of patients with lupus, which is a rare disease •Inspirit the professional cycle team composed of diabetic patients •Deliver the flower basket produced by employees of Mundipharma Korea to the •Emotional support program for patients in rare and orphan disease andfamilies •Arts & culture•Arts programs for adult patients and their families with rare or chronic •Menarini Korea’s brand ‘Fulcare’ holds campaign to raise funds to help single •Download the application 'Everyday Fulcare' or post a picture on this app will people•6,000 participated 1st campaign in April and accumulated funds totaling 2nd campaign•And in July, accumulated funds totaling 3million KRW were 03. Management lupus seniors patients Myeloma Activities Program Campaign Green Tree & Donation Love Action the disabled Green Santa World Cancer Tour deTour Novo Peace in Mind Healing Gallery Making Maracas Making treating Multiple treating Support costs for Disabled Support Disabled Making Wish Bear Athletic Meet with Support diagnosis Rare Disease 7,000 help single mom and Handicapped PersonHandicapped lupus erythematosus. lupus Support for HIV/AIDS Volunteer Activity for 'CheerYou' Program prevention, diagnosis Support patients with Donation for the local blood cancer patients CLOVER-ChildLOVER Education program for ‘Fulcare’ campaign to patient who suffer from “Hope” Flower Basket andeducation program Prevention Month Event expense for low-income • Ltd Ltd. Ltd. Ltd. BMS BMS Pfizer Pfizer Korea Korea Korea Ltd. Korea Ltd. Lilly Korea Korea Ltd.. Company GSK Korea Johnson & Celgene co. Novo Nordisk AbbVie Korea Mundipharma Pharma Korea sanofi-aventis Novartis Korea Janssen Korea Pharmaceutical Pharmaceutical Gilead Sciences Pharmaceuticals Pharmaceuticals DKSH Korea, Ltd. Roche Korea Co., Lundbeck Korea A. Menarini Korea Johnson S&D LLC. 02. Partnership and Collaboration Major Programs Global pharmaceutical companieswork better for treatment environment including enhanced physical condition and mental health patients. of Drug Development 01. and Supply Support for Patients CSR Activities 04. Major Activities Major income or North Korean children in need in need with short height with ChildFund including local children in need, in partnership with Save the 8m KRW thru voluntary activities at Seoul office located near its development center in Pyeongtaek. the company's matching grants that started from 2009 treatment children to with cleft lips, cleft palates and other facial Knit the beanies for newborn babies in Africa and Asia not lose to to Bayer’sto Banwol production site the body heat. The hats made by the employees will be sent the to Children from 2013 Gangwon Children's Welfare Center for helping holistic development of children in the nation future jobs children to of lower-income families with cancer family members suffer from mental diseases field activities the to students of Jinwi High School, which is Sharing People Grand Prize in 2015 upcoming Medical Missions organized by Smile Asia. under the slogan "Please protect children's eye" community facility, a direct agency of the Children’s Foundation community service in Africa and give hope underprivileged to people such as patients, and low and support Smile Menarini Asia*, volunteer group will join the children opportunity take to part in 8 day trekking the to Mount Kenya and children with an aim educate to the importance of agriculture. our children's eyes against environment which damages the eyes, education on how drugs for animal health are made through visit patients. newborn babies warm to their body. deformities donate for the children in need in Korea and Africa diseases and pest control through laboratory experiment and schools, youth centers and surrounding communities in Thailand support the to teenagers * Smile Asia is a charity dedicated providing to life-transforming •GE Leadership•GE programs for high school students in Paju-city •Volunteer for children•Volunteer with disability by visiting the Hanlove •Various fund-raising•Various and volunteering •Integrated the fund raised through employees' salary donation and the•Received Minister of Health and Welfare Award at the 4th Korea global campaign•A initiated by the Orange United that gives GSK Korea employee•A participated in the event, raising more than CSR events•Annual from 2000 until 2015 raise to social interest in •Provide sport•Provide and play-based learning activities selected to •Merck Biopharma•Merck supported cost of growth treatment for children •As "Menarini"•As continue promote to CSR work in the region •Provide Scholarships,•Provide mentoring and chances of experiencing •Mentoring program •Provide scholarships•Provide college to students in financial difficulties •Provide financial•Provide and emotional support f or teenagers whose college•Operate students mentoring group provide to emotional •Try to make to bright and healthy•Try future for children by protecting •The 5th spring picnic•The with the children from Good Neighbors •'Roche Groups' representative•'Roche CSR program support to Africa year•Every around 100 employees are participating walk to and •Movement for•Movement saving 1 million children in the poorest countries •Offer students•Offer studying veterinary medicine at university •Provide agriculture•Provide class and rice transplantation activity to better•Provide understanding of modern agriculture, plant Sustainable 03. Management village Program Students newborns Smile Asia Campaign Hope Fund Scholarship Trek for KidsTrek Paul Janssen ChildFund for 'Right Play' to Welfare Center Bayer Children Orange United Children's Walk on Life Science Agriculture Class Agriculture GE WISET Global Pfizer Scholarship GSK Hope Concert Paju-GE Crotonvile Knitting save to the Mentoring Program Love Eye Campaign Gangwon Children's Leadership program Bayer Youth Academy The spring picnic with Education Program for unprivileged neighbors unprivileged Sharing love in Hanlove Veterinary Medicine School Ltd. Ltd. BMS Pfizer Pfizer Korea Korea Company Korea Ltd. Korea Ltd.. GSK Korea Johnson & Bayer Korea AstraZeneca GE Healthcare Janssen Korea Pharmaceutical Pharmaceutical Pharmaceuticals Pharmaceuticals Lundbeck Korea DKSH Korea, Ltd. Roche Korea Co., Merck Ltd. Korea 02. Partnership and Collaboration A. Menarini Korea Johnson S&D LLC. Major Programs Global pharmaceutical companies help healthy growth of our society through expandingsocietythrough our of growthhealthy help pharmaceuticalcompaniesGlobal educational opportunitieschildren for and adolescents in vulnerable social groups. Drug Development 2017 KRPIA2017 Annual Report 01. and Supply Support for Children and Youth 38

Social Contribution Social Contribution 41 CSR Activities 04. 2017 KRPIA2017 Annual Report Major Activities Major flu(the largest scale in Korea) have volunteered, adding up to 29,000+ hours of donated time and partnered with 250+ million hours to complete more than 4,000 projects in 65 countries. health healthcare big data, idea competition for advanced and innovative healthcare solutions ribbon marathon, wear the pink ribbon badges and run pink truck during the campaign retail chain, is in partnership with the Malaysian Federation of the Deaf(MFD) to facilitate NGO partner Work Together Foundation, and involved 50 Shire Korea employees restoring Eung-am Primary School’s rooftop garden and painting various pictures of plants on the Rica, Ghana, India and Guatemala. Famous Amos currently has nine deafemployees stationed at selected outlets in Malaysia volunteer in 8 developing countries during 2 weeks. the hiring, training and coaching to promote retail career opportunities for deaf employees. with digital technology/platform designed to contribute to creating a healthier Korean who work alongside hearing staff. Welfare Organizations in needed. Lilly employees have now volunteered more than 1 sponsorship for the elderly in Songpa district. society season underprivileged neighbors on a selected working day(biannual) charities, with activities in 300+ locations around the world. activity and 5,200 briquettes were served for underprivileged neighbors in Korea aging society, disease management, health care, medical and health information and area among kids in the community and support their dream about epidemic disease(i.e.MERS) and prevention organizations like WHO garden walls. give back to the communities they serve. In its third year running, 7,300+ Shire employees governments 24th) Ageing Index Seminar’, ‘Healthy Ageing etc. Talk’, •On 13 Oct the•On 2017, local project “Build a Dream-Growing Farm” was an initiative with •Merck Employee•Merck and their family members participated in briquette delivery volunteering employee•Various volunteering programs by celebrating anniversary of founding(April •Conduct various programs to support Single-parent families. in project•Joined of disclosing information on carbon •Optimized production processes and saved energy of eco-friendly•Use and renewable energies at facilities in Denmark •Making seasonal side dishes for low-income or living alone seniors •Conduct a variety of Healthy Ageing Initiatives such as ‘Korea Get Old Survey’, ‘Healthy •Support children in grandparents-children families to manage their mental and physical competition•Idea open to the public on topics such as chronic diseases, geriatric patients, •Support free vaccination opportunity to the underprivileged including homeless against •Support for self-reliance of homeless •Support accessibility of healthcare services to small scale elementary schools in remote •October is a special month for Shire as our offices around the world bend together to Cancer•Breast Awareness Campaign: Hand out breast selfexam teaching leaflets, join pick •All executives•All and employees of the company provide health-related volunteer services to Donation •Pharmaceuticals •Financially support the employees who are selected by the global Bayer group kimchi•Make and deliver Korean Thanksgiving Day's present to the elderly living alone volunteer•Have service for kimchi for the senior citizens living alone in Jungnang-gu, Seoul •Sponsorship for Cha Bum Kun Football Class to help promote physical and mental health Science•Dream Class to help underprivileged community kids encourage scientific thinking Malaysia•DKSH Consumer Goods own-brand, the Famous Amos chocolate chip cookies •Partnership with KSA forthe success of PyeongChang Olympics •Support health check-up and prevention for underprivileged multicultural families •Support cervical cancer vaccinations for low-income families in partnership with local and medicine•Vaccine donation for North Koreans to help relief works of international •Conduct tree-planting activities at Noeul Park on occasion of Arbor Day briquette•Give for love mark 10-year of Lilly•To Global Day of Service, Lilly Korea employees visited 8 Social CSR activity•New launched in 2011that selected 100 employees as ‘CHA ambassador’ 2011 11 employees to2017, •From of Lilly Korea participated in the project in Tanzania, Costa •Lundbeck Korea contributes to a local community through continuous volunteering and •Distribution of "Life Plus", the health & pharmaceutical journal at pharmacies: Contain data Sustainable 03. Management the Deaf Campaign Program Action Day Living Alone Living Contribution Volunteering Volunteering Songpa district Helping Hands : Partnership Day underprivileged Zuellig with Love Local Community Briquette Delivery For the sake of the multicultural family multicultural TakeAction activity Children Happiness Novartis Community Global Day of Service Global Day of Service Do-gatherCampaign Grand Parents-Grand A coal briquette event improvementactivities Tree PlantingTree Program Supporting Employees' Employees' Supporting Humanitarian donation Humanitarian Campaign for the Elderly Healthy Ageing Initiatives Senior Day Care Centre in Connecting Heart Abroad Pharmaceuticals Donation Pharmaceuticals Famous Amos partnership Visiting health checkup for Gift Donation to the Elderly Kim Jang Event and Holiday Week of Possibilities/AbbVie GE Sports Leadership Camp Environment protection and PEH Digital Open Innovation with Malaysian Federation of Ltd Ltd. Ltd. Ltd. BMS Pfizer Pfizer Korea Korea Korea Ltd Korea Ltd. Lilly Korea Company Korea Ltd.. GSK Korea Boehringer Bayer Korea Novo Nordisk Shire Pharma AbbVie Korea Korea Co., Ltd Pharma Korea GE Healthcare Sanofi Pasteur Novartis Korea Guerbet Korea Allergan Korea Zuellig Pharma Pharmaceutical Pharmaceutical Gilead Sciences Ingelheim Korea Lundbeck Korea Pharmaceuticals Pharmaceuticals DKSH Korea, Ltd. Merck Ltd. Korea 02. Partnership and Collaboration members of society. Major Programs Global pharmaceutical companies strive support to the development of localcommunities and help people pursue healthy and happy lives through various programs different for Drug Development 01. and Supply General PublicGeneral Support for the the Support for CSR Activities 04. Major Activities Major in colorectal cancer and head and neck cancer and in Korea under partnership with the Korean Cancer in 2012 international activities by discovering and recognizing healthcare issues and bring to positive improvement in healthcare access, by supporting social entrepreneurs healthcare field healthcare training program for them the Korean Association for Clinical Oncology established the Emperor in late Joseon Dynasty, and contribute to developmentto of medical science in Korea, award to the fertility research field under partnership with Korean those who have contributed elevating to the country’s who will transform the healthcare sector with innovative first German physician, served as a medical doctor to Korean medical science and human health and welfare, Pharmaceuticals Korea Society for Reproductive Medicine established in 2013 contribute development to of oncology medical science cancer and contribute oncology to research and entrepreneurs in healthcare industry, ‘Making More Health excellent medical scientists in November every year form establish a cooperative network in the field of life sciences development initiatives in Korea under partnership with research achievements of clinicians participation of Koreanhealthcare professionals in reputation through international cooperation Changemaker’ project launched with Ashoka Korea in 2014, Contributions Medicine to is designed promote to the solutions school develop to future talents in bio industry and provide scientists who have contributed the to development of and have supported social entrepreneurs working in the 1990 achievement and encourage technology development in academia experts from both countries participated to and Pfizer Pharmaceuticals Korea in 2006 and motivate to them continue to research Association established in 2011 Academy of Medicine of Korea and sponsored by Pfizer •Promote discovery•Promote of fundamental solutions unsolved to •The award encourage to academic•The research activities •Support research•Support funds in recognition of outstanding cherish achievements Richard of Dr. •To Wunsch, the award encourage to clinical•The research in colorectal •In Korea, as the first•In attempt discover to potential social •MOU with several•MOU university, college, and specialized high award contribute to recognize to •The scientific annual event that government•An officials, industry and •Korean Medical•Korean Association Pfizer Prize for International •Established jointly by Korean Medical Association(KMA) •Korea’s most prestigious•Korea’s medical award hosted by National •Established in 1999 discover to and recognize medical Sustainable 03. Management Award Award talents Project Program Medicine Symposium Korean Cancer Korean Medical Scientific Award Scientific Scientific Award Scientific Contributions to Swiss Life Science Association Pfizer Korean Society for Association-Merck Association-Merck Making More Health Prize for International Sponsorship of Korea- Korean Association for Merck Scientific Award Bayer Clinical Medicine Wunsch Medical Award Pfizer Medical Research ReproductiveMedicine- Clinical Oncology-Merck Oncology-Merck Clinical Training program for Bio Pfizer Pfizer Korea Korea Ltd Company Boehringer Boehringer Bayer Korea GE Healthcare Ingelheim Korea Pharmaceuticals Pharmaceuticals Merck Ltd. Korea Novartis Korea Ltd 02. Partnership and Collaboration ideas from health care industryhealthcareglobalenhance ideasfromdeveloping andmedical local fieldsto science of Major Programs Global pharmaceutical companies promote various activities including excavating innovative competitiveness by vitalizing the specialties of pharmaceutical companies. Drug Development 2017 KRPIA2017 Annual Report 01. and Supply Development of of Development Science Medical 40

Social Contribution Social Contribution - 43 CSR Activities 04. Major Activities Major 2017 KRPIA2017 Annual Report implemented throughout the month of April each year all towards needed neighbors December 2015 beyond their own lives towards the communities and needs by employees for the low-income families Forest' caring and tree planting Korea delivered 1,000 coal briquettes the to low-income Foundation. to neglectedto and low-income families and social welfare for supporting various activities for the elderly.(e.g. take part in various voluntary activities, and look for underprivileged people including senior citizens and kids facilities contribute the to local community communities on a selected working day children and support living necessities developing countries developing program neighbor to in need of Seoul Briquette Bank in rooms, located in Yeongdeungpo in May 2016 neighborhoods. via employees voluntary participation on every 3rd Saturday of each month over the country under the themes of "Patient" and "Planet" of others volunteer activities regularly. volunteer seniors, etc.) arranged by Yeongdeungpo Borough Office deliver to Accompanying the senior with wheelchair, Providing snack for •Reforming sneakers•Reforming for children in developing countries for shoes•Fundraising be to provided for children in •Paper the cell for Jjokppangchon,•Paper the slurbs consisting of tiny an annual•Hold event of making kimchi for neglected people •Practice the love•Practice of the environment through Family 'J&J and•Employees their families from volunteer club of Lilly •Employee volunteering•Employee team H2O leads CSR activities to •Participate in Love Briquette Movement,delivering briquettes activities•Volunteering of our employees for local •Also donated fund for•Also the Korean Children Leukemia •Provide sport•Provide and play-based learning the to blinded out•Helped at a local soup kitchen for homeless people •“Dda-Son(warm hands)” provides•“Dda-Son(warm quarterly voluntary services •Starfish periodically•Starfish visits a senior day care centre •A. Menarini Support•A. JuMong Center for donations and •Launched in 2008,•Launched Employees’ voluntary service programs •A company-wide employee•A engagement program •Participate in the event of making kimchi for the winter •An annual event upon•An which global Shire employees together •Bake with Love voluntary•Bake work: Breads baked and delivered orphanages•Visit and senior citizens living al one for support Sustainable 03. Management love Hope Center Starfish as One) Program Good Day J&J family Orange Day Afforestation of Healthcare) of Love in Action Delivery Service Activity Society) A Coal Briquette Zuellig with Love Food event Truck Managing Korean ManagingKorean Making Kimchi for Sharing kimchi with a local soup kitchen Volunteer Activity at Community Services Lundbeck CSR Club: H2O(Hearts & Hands One Foundation Day Global Day of Service Healing shoes making Community Service at JuMong Rehabilitation Corporation(Executives Warm Hands(Volunteer Hands(Volunteer Warm Ltd. BMS Korea Korea Co., Ltd Company S&D LLC. Korea Ltd Lilly Korea Korea Ltd.. GSK Korea Servier Korea Shire Pharma AbbVie Korea sanofi-aventis Korea Co., Ltd. GE Healthcare MSD Korea Ltd. Zuellig Pharma Pharmaceutical Pharmaceutical Genzyme Korea Lundbeck Korea DKSH Korea, Ltd. Sanofi Pasteur Ltd. Allergan Korea Ltd A. Menarini Korea LEO Pharma Korea Johnson & Johnson Johnson & Johnson 02. Partnership and Collaboration tical actions healthy of andlove. life Employeesglobalpharmaceutical of even club internal companies anvoluntarily workin Major Programs with their busy daily life. Consistently maintained internal volunteer club shows the prac the shows club volunteer internal maintained Consistently life. daily busy their with Drug Development 01. and Supply Internal Internal Volunteer Club Volunteer CSR Activities 04. Major Activities Major Sustainable 03. Management in Taiwan(2014) in bazaar were sent to the seniors in local community. located in Sangil-dong, Gangdong-gu. PfizerLINK and LINKsium, the money will be donated to Community Chest of Korea Kong(2014) Korea by matching donation. International every month. their education around the world towards patients withrare disease to more than 20 different social centers, including temples, churches, shelters, the direct delivery of milk to those social centers, DKSH also associated with other successfully entereduniversity and three are currently in high school underprivileged children in Malaysia(2014) at the end of the year to buy books and school supplies for children living in remote areas cancer patients and their family of living’ for pediatric cancer patients & their family products at the internal online shopping mall while the company matches grants million to the Child Fund Korea awarded to students orphaned by the disaster who need assistance to continue Cambodia(2014) in children against disease written by liver disease patients celebrate its 60 years of business in Korea collaborated with the brand Devondale milk to implement a community service campaign. In this campaign, DKSH donated thousands of boxes of Devondale milk and nursing homes in the Ho Chi Minh City area and surroundings. In addition to charityorganizations and youth groups towork together tosend products toremote areas where people are in need. of seven years until they graduate from college. date, seven To of the students have employee-volunteered bazaar for supporting low income pediatric cancer patients donated to Salvation Army’s Duri Home welfare facilities for single moms Volunteer Foundation to purchase medical devices. Allergan Korea heldan employee-volunteered activity for supporting heating bills. •Support children in the 3rd world countries by providing old clothes •Donation money is raiseddepending on the number of HCPs participating in •A. Menarini•A. Korea donated 20 used laptops to ‘Jumong Rehabilitation Center’ laptops help•Those them with on-line programs, working and others. •Donations generated from fund raising contributed by employees for pediatric •Donation to Korea Pediatric Cancer Foundation to support ‘emergent medical cost •Seed pencils•Seed planted in the pot are transformed as flower pots which will be •Reserve 10% of the expenses whenever our employees purchase GSK's consumer the•Donate money to Save the Children to help local children •Medicine Donations: Botulinum donations Toxin for patients with cerebral palsy •Employees voluntarily donated the items to raise the donation. All incomes from the •Established after the Great East Japan earthquake and tsunami of March 2011 and •Support the students’ education financially without obligation for a maimum term Charity•Alladdin : raising funds for welfare homes for the elderly and Christmas•Donate presents : donating Christmas presents to disadvantaged children a rugby•Sponsor day : sponsoring a rugby day with disadvantaged and disabled and•Prepare distribute food : preparing and distributing food to the needy in Hong •Charity auction of art works created based on themes of experiences in fighting celebrate 140th anniversary•To of Eli Lilly and Company, Lilly Korea held an profits•Bazaar were donated to the Social Welfare Organization Community Chest of •Fund raising•Fund walk campaign: Every walking step of employees become donated celebrate the 21st anniversary•To of Allergan Korea’s establishment in Korea, 2015, Bayer•In Korea hosted “Let’s Walkathon!” in Yeouido Han River Park to 5 million•Approx. steps were counted, which translated into a donation of KRW 10 •Donate a portion•Donate of employees’ salaries voluntarily to Korea Food for the Hungry •From June 28•From to July 10, 2016, the Business Unit Consumer Goods team in Vietnam money raised•The by DKSH-CCC funfair is donated to the Princess Mother's Medical family A-Walk of Love (OTCAN) Disability’ Donation Program Employee Employee Employee- Employee- Donation for Donation for International Hope Gallery Volunteering and Donation Fantree Club- Fantree of People with Devondale milk Let’s Walkathon pediatric cancer Support for ‘Day patients and their Link Hope Project Share Flower Pots laptop to ‘Jumong Collaboration with Donation to Korea DKSH-CCC funfair Fantree Scholarship 10% Benefit Sharing Food for the Hungry Volunteered Bazaar Alladdin charity ,etc. Good-hearted Pfizer Rehabilitation Center’Rehabilitation Charity Donation Box volunteered Donation volunteered VolunteeredBazaar& Ltd BMS Pfizer Pfizer Korea Korea Ltd Korea Ltd. Korea Ltd. Lilly Korea Company Korea Ltd.. GSK Korea A. Menarini Bayer Korea AbbVie Korea Mundipharma Allergan Korea Pharmaceutical Pharmaceutical Gilead Sciences Ipsen Korea Ltd. 02. Partnership and Collaboration Lundbeck Korea Lundbeck Korea Pharmaceuticals Pharmaceuticals DKSH Korea, Ltd. programs. Events delivering the contribution people to in needs isbeing progressed. Employees the of global pharmaceutical companies actively participate in fund raising Major Programs Drug Development 2017 KRPIA2017 Annual Report 01. and Supply 42 Donation

Social Contribution A Pioneer in the Global Healthcare Industry

Global pharmaceutical companies are active in the global market based on R&D to promote a better healthcare environment for mankind

Korean Research-based Pharmaceutical Industry Association Directory Directory

44 2017 KRPIA Annual Report 2017 KRPIA Annual Report 45 Abbott Korea AbbVie Korea

The most trusted & leading biopharma company transforming people’s lives by delivering A Promise For Life innovative solutions

History History Company Profile 2016 Korean subsidiary basis Company Profile 2016 Korean subsidiary basis 1980 Established Abbott 1988 Established Abbott 3F Samtan Bldg., 421, Yeongdong- 6F Samtan Bldg., 421, Yeongdong- Company Abbott Korea Address Korea branch Company AbbVie Korea Address 1999 Galien Award for ‘Kaletra’ 2007 Galien Award for ‘Humira’ daero, Gangnam-gu, Seoul, Korea 1988 Established Abbott daero, Gangnam-gu, Seoul, Korea 2013 Established AbbVie President SY Lee Headquarters USA Korea President Lew Hong-Ki Headquarters USA Korea branch 1989 Completed Ansan plant. 2016 - Working Mother Website www.abbott.co.kr Branches Daejeon, Gwangju, Busan, Daegu Commenced the Website www.abbvie.co.kr Annual Sales KRW 76 billion Magazine, ‘100 Best Companies for Working production of Telephone 02-3429-3500 Annual Sales KRW 177.4 billion Telephone 02-3429-9300 Mothers’(fourth diagnostic equipment consecutive year) and medical substances - Diversity Inc., Top 2006 Established ‘Abbott 50 Companies for Diversity(second Education Center’ consecutive year) Employment Product R&D Investment - International Medical Employment Product R&D Investment Corps, Global Citizen Award 260 20 about 1,345 101 11 Approx. 4.7 2017 - Listed on Dow Jones USD: million KRW: trillion Sustainability Index(DJSI) World and DJSI (Based on Global HQ) (Based on Global HQ) North America(fifth consecutive year after foundation in 2013) Main Products •Humira: Rheumatoid Arthritis, Axial Spondyloarthritis, Crohn’s Disease, Ulcerative Colitis, - Biotech Industry Main Products •Klaricid: Upper/lower respiratory tract infection, Helicobacter infection Psoriatic Arthritis, Noninfectious Uveitis, Pediatric Crohn’s Disease, Juvenile Idiopathic Arthritis, Leader in Dow (name/indications) (name/indications) •Depakote: Bipolar disorder, Epilepsy seizures Enthesitis-related Arthritis, Pediatric Plaque Psoriasis, and etc. Jones Sustainability Index(second •Zemplar: Secondary hyperparathyroidism associated with chronic renal insufficiency •Ganaflux: Short-term treatment of gastric ulcer&duodenal ulcer, consecutive year) •Synagis: RSV infection in lower respiratory tract Treatment of erosive esophagitis & symptomatic GERD(heartburn, - Fortune, The World's •Viekirax/Exviera: Hepatitis C Virus(HCV) infection(genotype 1a, 1b and 4) Most Admired regurgitation etc.), Maintenance of healing of erosive esophagitis & • : HIV infection Kaletra Companies gastric ulcer •Duodopa: Advanced Parkinson’s Disease with motor fluctuation - Patient View, ranked 2nd place on corporate •Rytmonorm SR: Antiarrhythmic indicated to prolong the time to Major R&D Status Clinical Trials recurrence of symptomatic atrial fibrillation(AF) - Total 40 projects in 243 institutions with 750 medical professionals reputation analysis, based on patient •Hidrasec: Supplementary oral therapy of providing fluids and salt to R&D Pipeline organizations’ survey treat acute diarrhea - Liver Disease(HCV), Neuroscience(Alzheimer’s Disease, Schizophrenia, Multiple Sclerosis, Advanced amongst pharmaceutical Parkinson’s Disease) companies(third •Cholib: Complex dyslipidemia - Immunology(Uveitis, Hidradenitis Suppurativa, etc.), Kidney Disease(Chronic Kidney Disease, Acute consecutive year) Kidney Injury) - Robecosam, Gold Class - Oncology(Chronic Lymphocytic Leukemia, Multiple Myeloma, Breast and other cancers), Women’s Sustainability Award Awards •Received $10 million Export Tower Award from the President(1992) Health(Endometriosis, Uterine Fibroids) •Received Best Foreign Corporation Award from Citizen’s Coalition for Major CSR Activities •Week of Possibilities/AbbVie Action Day Economic Justice(2008) All employees of the company provide health-related volunteer services to underprivileged •Received ‘Excellence Award of Korea Love-Sharing Volunteer Awards’ neighbors on a selected working day(biannual) from National Council of NPO(2010) •Welfare Information brochures for patients with “rare diseases” and “liver diseases” Production and release of welfare information brochure for “Rare disease patients” and “Liver •Received Asian CSR Award(2011) disease patients”, in conjunction with Korean Association of Medical Social Workers and related •Received ‘Happy and Fun Workplace’ by Ministry of Culture, Sports and organizations such as Korean Organization for Rare Disease, Korean Association for the Study of the Tourism(2012) Liver and LiverKorea Awards •Innovation Award: Korea Chamber of Commerce ＆ Industry(2016) •Strong small company with the young: Ministry of Employment and Labor(2016) •Great Place to Work Award: GWP Korea(fourth consecutive year /2016) Directory Directory •Great Place for Korean Women to Work Award: GWP Korea(third consecutive year/2016) •Family Friendly Workplace by Ministry of Gender Equity and Family(2013-2018) •‘Best Workplaces in Asia’–GPTW Institute®(2015) •‘Best Labor-Management Culture Enterprises’ from Ministry of Employment and Labor(2015) •‘Mother Friendly Corporate' by UNICEF(2015) •‘Joyful Workplace, Happy Company’ from Ministry of Culture, Sports and Tourism(2014) •President Lew Hong-Ki received Prime Minister’s Award from Ministry of Food and Drug Safety on ‘Medicine Day’(2013)

46 2017 KRPIA Annual Report 2017 KRPIA Annual Report 47 Actelion Allergan Pharmaceuticals Korea Ltd. Korea Ltd. BE BOLD–Build Bridges, Innovation For Patients Power Ideas, Act Fast, Drive Results

History History Company Profile 2016 Korean subsidiary basis Company Profile 2016 Korean subsidiary basis 1997 Established Actelion Ltd. 1950 Established Allergan Actelion Pharmaceuticals 14F GT Tower, Seocho-Daero 411, Company Telephone 02-2112-2833 2005 Established Actelion Company Allergan Korea Ltd. Address Inc. Korea Ltd. Pharmaceuticals Korea Seocho-gu, Seoul, Korea 1995 Established subsidiary 6F Gangnam Finance Center., 152, Ltd. President Angie Kim Headquarters Dublin, Ireland in Korea President Tanaka Hiroaki Address Teheran-ro, Gangnam-gu, Seoul, Korea 2009 Started direct Website www.allergan.co.kr Branches Daejeon, Daegu, Gwangju, Busan business for medical Website www.actelion.co.kr aesthetic products Telephone 02-3019-4500 Annual Sales KRW 72.6 billion 2009 Established Samil Allergan Ltd. 2015 Integrated Samil Allergan Ltd.

Employment Product R&D Investment Employment Product R&D Investment

12 3 about 569 120 45 about 2.5 CHF: million USD: billion (Based on Global HQ) (Based on Global HQ)

Main Products •BOTOX® Injection: Strabismus, Upper limb spasticity etc. Main Products •Traclear: Pulmonary arterial hypertension, Systemic sclerosis related •JUVEDERM® VOLUMA® with Lidocaine: Correction of facial wrinkles and helps (name/indications) digital ulcer (name/indications) temporarily restore facial volume ® ® ® ® •Zavesca: Gaucher’s disease, Niemann-Pick Type C •JUVEDERM VOLIFT with Lidocaine, JUVEDERM VOBELLA with Lidocaine: Temporary enhancement of facial wrinkles and lip volume •Opsumit: Pulmonary arterial hypertension •NATRELLE® 410 Silicone-filled breast implant, NATRELLE® INSPIRA® Silicone- filled breast implant: Breast augmentation and reconstruction •RESTASIS® eye drops 0.05%: Increase tear productions in patients whose tear Major R&D Status Clinical Trials production is presumed to be suppressed ® Total 3 projects in 10 institutions with 60 medical professionals and 51 •COMBIGAN eye drops: Open angle glaucoma, Ocular hypertension •OZURDEX implant 700㎍: RVO(Retina vein occlusion), Posterior uveitis patients •LUMIGAN® eye drops 0.01%: Open angle glaucoma, Ocular hypertension •RELESTAT® eye drops 0.05%: Allergic conjunctivitis R&D Pipeline •LASTACAFT® eye drops 0.25%: Allergic conjunctivitis - Cardiovascular disease: Pulmonary arterial hypertension - Infectious disease: Antibiotics - Nervous system disease Major R&D Status Clinical Trials - Immune system disorder Total 11 projects in 200 institutions with 2,600 patients - Metabolic disease R&D Pipeline - Neuromuscular Disease: Spasticity, Chronic Migraine - Ophthalmology: Glaucoma, DME, AMD - Urinary system: OAB, NDO Major CSR Activities Support on patients group of Pulmonary Hypertension

Major CSR Activities •CSR activities Provide sport and play-based learning to the blinded children and support living necessities •Employee-volunteered Donation Allergan Korea donated the whole fund from an employee-volunteered donation activity

Directory based on BOLD FOR LIFE as Allergan Organization culture. Directory •Pharmaceuticals Donation - Serviced institutions and served people: 5 institutions for over 4,180 people - Supporting medial aid: 9 drugs – total 1,700 units - Supporting expenses: KRW 1.0 billion

48 2017 KRPIA Annual Report 2017 KRPIA Annual Report 49 Amgen Korea AstraZeneca

Korea Push the boundaries of science To Serve Patients to deliver life-changing medicines

History History Company Profile 2016 Korean subsidiary basis Company Profile 2016 Korean subsidiary basis 2015 Establish the Korea 1913 Established Astra AB Company Amgen Korea Telephone 02-3434-4800 17F Luther Building., 7-20, Sincheon- Corporate Body Company AstraZeneca Korea Address 1926 Established dong, Songpa-gu, Seoul, Korea Imperial Chemical 14th Floor, Seoul International Tower, Industries(ICI) President Noh Sang-Kyung Address Teheran-ro 203, Gangnam-gu, Seoul, President SeWhan Chon Headquarters UK (ICI-predecessor of Korea Zeneca) Website www.astrazeneca.co.kr Branches Busan, Daegu, Gwangju, Daejeon 1992 Established Astra Website www.amgenkorea.kr Headquarters US Korea Telephone 02-2188-0800 Annual Sales about KRW 317 billion 1997 Established Zeneca Korea 1998 Officially announced merger between Astra AB and Zeneca 1999 Changed company Employment Product R&D Investment Employment Product R&D Investment name to AstraZeneca Korea as Astra merged 50 5 about 3.8 357 39 about 5.9 with Zeneca 2005 Launched ‘Hope Fund’ USD: billion USD: billion for CSR activities for (Based on Global HQ) (Based on Global HQ) children of lower- income families with cancer patients 2006 Concluded a MOU •Forxiga/Xigduo XR: Type 2 diabetes Main Products •Blincyto: Relapsed or refractory acute lymphoblastic leukemia(ALL) Main Products with Ministry of Health •Brilinta: Acute coronary syndrome and Welfare for ‘2010 (name/indications) •Kyprolis: Relapsing multiple myeloma (name/indications) •Lynparza: Recurrent ovarian cancer with BRCA mutation Expansion of Bio-hub • : Osteoporosis treatment Prolia •Tagrisso/ Iressa: Non-small cell lung cancer of Korea R&D and Clinical Exchange and •Xgeva: Prevention of SRE(Skeletal related event) and GCTB(Giant Cell •Symbicort: Asthma and COPD Tumor of Bone) treatment Cooperation’ 2011 Concluded a MOU Major R&D Status Clinical Trials with Ministry of Total 50 projects in 75 institutions with about 200 medical professionals and about Health and Welfare 3,500 patients Major R&D Status Clinical Trials for ‘Improving Korea’s Capabilities Total 20 projects in 50 institutions with 127 medical professionals and R&D Pipeline of Developing 825 patients - Oncology, Respiratory, Inflammation and Autoimmunity, Cardiovascular and Metabolic New Drugs and Expansion of Research R&D Pipeline Particulars Cooperation in Hematological cancer, Solid cancer, Cardiovascular disease, - In collaboration with Korea Health Industry Development Institute, it conducted a Healthcare Area’ immunological disease, muscular skeletal disease program of providing research funds, investigational compound and network with researchers at global headquarters by selecting translational research projects of 4 Korean scientists in oncology once a year. - Started first-in-Asia basket trial and pre-clinical study jointly with researchers in Korea. - Started Phase I study in human participants research of new drug candidates for lung cancer and breast cancer.

Major CSR Activities •Hope Fund Provide scholarships, mentoring and chances of experiencing future jobs to

Directory children of lower-income families with cancer patients. Directory

Awards •Received The Best Award in CSR sector in the Korea PR Awards(2010) •Received Best Award in Community Relationship sector in the Korea PR Awards(2013) •Received Prize in the Best company with 'work-family balance'(Ministry of Employment and Labor)

50 2017 KRPIA Annual Report 2017 KRPIA Annual Report 51 Bayer Korea BMS Pharmaceutical Korea Ltd. Working Together Science For A Better Life For Patients

History History Company Profile 2016 Korean subsidiary basis Company Profile 2016 Korean subsidiary basis 1863 Established Bayer 1997 Established BMS Korea 6th fl. Samsung Boramae Omni Tower, 23, BMS Pharmaceutical 12F Haesung 1 Bldg., 504 Teheran-ro, 2000 Launched 'Plavix' to Korea Company Bayer Korea Address 1955 Started business in Company Address market Boramae-ro 5-gil, Dongjak-gu, Seoul, Korea Korea(Crop protection) Korea Ltd. Gangnam-Gu, Seoul, Korea 2006 'Plavix' reached No. 1 prescription drug in the President Ingrid Drechsel Headquarters Leverkusen, Germany 1985 Constructed animal President Park Heasun Headquarters USA market(based on IMS data) 2007 Launched 'Baraclude' to health product plant in Korea market Head office in Seoul, over 10 branches & Banwol Website www.bms.com/kr Branches Seoul 2008 Launched 'Sprycel' to Korea Website www.bayer.co.kr Branches market research center in major cities, 3 plants 1989 Established Bayer Telephone 02-3404-1300 Annual Sales KRW 190 billion 2010 'Baraclude'reached No. 1 Korea prescription drug in the Telephone 02-829-6600 Annual Sales KRW 334.7 billion market(based on IMS data) 2005 Integrated OTC drug 2011 - KFDA approved expanded indication for 'Sprycel' as a division of Roche with first-line treatment Bayer Korea - Launched 'Orencia' to Korea market 2007 Integrated Schering 2013 Launched 'Eliquis' to Korea Korea with Bayer Korea Employment Product R&D Investment market 2014 KFDA approved 'Yervoy' for Employment Product R&D Investment 2015 Acquisition of US- melanoma based Merck’s OTC 209 12 about 4.9 2015 - KFDA approved 'Opdivo' for about melanoma 554 140 4.7 drugs USD: billion - KFDA approved (Based on Bayer EUR: billion (Based on Global HQ) 'Daklinza'+'Sunvepra' for 2015 Bayer MaterialScience hepatitis C (Based on Global HQ) Korea Ltd.) independence - KFDA approved expanded indication for 'Eliquis' as a under the new name first-line treatment • Baraclude: Chronic hepatitis B - Granted '2015 Best Family Covestro Main Products Friendly Certificate' by the • Sprycel: Chronic leukemia Main Products •Xarelto: Anticoagulants 2016 Currently operating (name/indications) Ministry of Gender Equity • Orencia: Rheumatoid arthritis and Family (name/indications) •Nexavar: Progressive Renal cell carcinoma, Hepatocellular carcinoma, Bayer Korea Co. and • Eliquis: Stroke and systemic embolism for a patient with nonvalvular AF 2016 - KFDA approved 'Opdivo' Differentiated Thyroid Cancer Bayer CropScience Ltd. • Daklinza: Chronic Hepatitis C for non-small cell lung • Sunvepra: Chronic Hepatitis C cancer(for the first-time •Aspirin Protect: Cardiovascular Disease in Korea) • Yervoy: Melanoma •Yaz: Contraception, Premenstrual Dysphoric Disorder, Moderate Pimple - Granted 'Prime Minister • Opdivo: NSCLC(Non-Small Cell Lung Cancer), Melanoma Award for 2016 Gender •Berocca Performance: Effervescence multiple vitamin Equalization Best Enterprise' by the Ministry of •Eylea: Diabetic Macular Edema, Neovascular(Wet) Age-Related Macular Major R&D Status Clinical Trials Employment & Labor Degeneration Total 27 projects in 115 institutions with 115 medical professionals and 575 patients 2017 - Granted ‘Excellent Company & Union Partnership R&D Pipeline Enterprise of the year’ by Cancer(lung cancer, liver cancer, renal cancer, melanoma, hematological cancer), the Ministry of Employment Major R&D Status Clinical Trials & Labor Immunoscience, Cardiovascular Total 46 projects in 250 institutions with 250 medical professionals and 1,513 - KFDA approved expanded patients(cumulative) Particulars indication for 'Opdivo' as treatment for, kidney cancer, - Nivolumab for hepatocellular carcinoma: urothelial carcinoma cancer, R&D Pipeline Received approval for the second line treatment by the U.S. FDA in 2017 head and neck cancer, Cancer, Cardiovascula, Heamatologic diseases Received positive opinion recommending the approval by CHMP in 2017 Hodgkin lymphoma and - Nivolumab for metastatic colorectal cancer: combination therapy with Yervoy for melanoma. Received priority review by the U.S. FDA in 2017 Major CSR Activities •Bayer Clinical Medicine Award - Nivolumab for urothelial carcinoma(UC) Support research funds in recognition of outstanding research achievements of Received approval for the second line treatment by the U.S. FDA and The European clinicians commission(EC) in 2017 - Nivolumab for squamous cell carcinoma of the head and neck(SCCHN): •Supporting Employees' Volunteering Received approval by The European commission(EC) in 2017 Financially support the employees who are selected by the global Bayer group - Nivolumab and ipilimumab combination for melanoma: •Kim Jang Event and Holiday Gift Donation to the Elderly Received approval for the first-line treatment by the U.S. FDA in 2016 Make kimchi and deliver Korean Thanksgiving Day's present to the elderly living - Nivolumab for classical hodgkin lymphoma(cHL): alone Received accelerated approval designation by the U.S. FDA in 2016 - Nivolumab for urothelial carcinoma(UC) and squamous cell carcinoma of the head and

Directory •Bayer Children Agriculture Class neck(SCCHN): Received breakthrough therapy designation by the U.S. FDA in 2016 Directory Provide agriculture class and rice transplantation activity to children with an aim to educate the importance of agriculture Major CSR Activities •Children Support Activities - Fund raising for Korea Food for the Hungry International •Education Program for Veterinary Medicine School Student: - ‘Spring picnic’ with the children from Good Neighbors Gangwon Children's Welfare Offer students studying veterinary medicine at university education on how drugs •Disabled Support Activities for animal health are made through visit to Bayer’s Banwol production site 'Healing picnic' with disabled in National Rehabilitation Center •Campaign for the Elderly Living Alone Volunteer service for kimchi for the senior citizens living alone in Jungnang-gu, Seoul

52 2017 KRPIA Annual Report 2017 KRPIA Annual Report 53 Boehringer Bracco Ingelheim Korea Imaging Korea Company That Provides More Value through Innovation Useful Contrast Media Solutions

History History Company Profile 2016 Korean subsidiary basis Company Profile 2016 Korean subsidiary basis 1885 Founder Albert 1927 Founded Bracco Boehringer Ingelheim 16F Yonsei Severance Bldg., 10, Tongil-ro, (3 & 4F, Shinsung Bldg.) 233 Yeoksamro, Company Address Boehringer establishes Company Bracco Imaging Korea Address Group Korea Jung-gu, Seoul, Korea Gangnamgu, Seoul, 06225, Korea manufacturing plant in 1970 Lopamidol developed President Kihwan Park Headquarters Germany Ingelheim, Germany President Yoo Tae-Sook Headquarters Italy and successfully 1895 Pioneered released worldwide Head office in Seoul and branches in Head office in Seoul and branches in Website www.bikr.co.kr Branches biotechnological Website www.bracco.com Branches 1980 Exploited an Daejeon, Daegu, Kwangju, Busan processes by Busan, Daegu, Daejeon and Honam international market Telephone 02-709-0112 Annual Sales About KRW 266.4 billion manufacturing lactic Telephone 02-2222-3500 Annual Sales about KRW 32 billion starting from the US acid using bacterial market scale ※Sold through Ilsung 1964 Established Pharmaceutical’s technological alliance license-out of over Employment Product R&D Investment with C.H. Boehringer Employment Product R&D Investment 25 years Sohn of Germany 2009 Established subsidiary 256 30 about 4 1976 Establishment of 33 11 about 62 EUR: million KRW: trillion Korea-Germany’s joint (Based on Global HQ) (Based on Global HQ) venture 1986 Germany’s first biologics manufacturing plant Main Products •Jardiance: Diabetes Main Products Contrast Media •Trajenta: Diabetes founded in Biberach - Iomeron (name/indications) (name/indications) •Twynsta: Essential Hypertension 2006 Sales exceeded KRW - Iopamiro • : COPD, Asthma Spiriva 100 billion •Vahelva: COPD - Prohance •Pradaxa: Stroke and systemic embolism in patients with non-valvular atrial fibrillation 2013 Received the Social - Multihance •Giotrif: NSCLC Contribution Award for - SonoVue Happiness hosted by Major R&D Status On-going Clinical Trials Total 16 projects in 395 institutions with 1101 medical professionals and 2535 patients the Korea Employers’ Medical Devices Federation and Korea Therapeutic area focus - CT Exprès Oncology, Respiratory, Cardiovascular, Metabolic disease, Immunology and other rare disease Journalists’ Federation - Empower CTA Particulars 2013 Sales exceeded KRW - Empower MR - Pan Asian Phase I project: The goal is to have an early evaluation of ethnic differences between 200 billion the Asian and the Caucasian population(i.e. comparing the PK and/or PD results with the Caucasian Phase I trials). It is done in collaboration with phase 1 units in research hospitals - Global Study Manager: Global Study Manager at BI Korea supervise and manage global phase Major R&D Status Clinical Trials I-phase IV clinical trials Participating Patient: about 2,100 - Clinical Program Medical leader: Involves in global clinical development for specific areas such as oncology and neurosciences R&D Pipeline New research on clinical development for contrast enhance ultrasound Major CSR Activities •Making More Health Project - Global CSR initiative with the goal of identifying fundamental solutions to unsolved healthcare issues diagnostic modality and to bring positive improvement in healthcare access, by supporting social entrepreneurs who will transform the healthcare sector with innovative solutions. Particulars - In Korea, as the first attempt to discover potential social entrepreneurs in healthcare industry, It concentrates efforts on developing diagnostic radiology, such as ‘Making More Health Change maker’ project launched with Ashoka Korea in 2014, and have supported social entrepreneurs working in the healthcare field. X-ray, ultrasonography, magnetic resonance and nuclear medicine, than developing therapies for treating diseases. •Wunsch Medical Award - To cherish outstanding achievements of Dr. Richard Wunsch, the first German physician, served as a

Directory medical doctor to the Emperor in late Joseon Dynasty, and to contribute to development of medical Directory science in Korea, the company has been conferring the award to excellent medical scientists in November every year form 1990. •Local Community Contribution - Sponsorship for Cha Bum Kun Football Class to help promote physical and mental health among kids in the community - Dream Science Class to help underprivileged community kids encourage scientific thinking and support their dream

54 2017 KRPIA Annual Report 2017 KRPIA Annual Report 55 Celgene co. DKSH Korea, A Preeminent Global Company Of Ltd. Our Vision Is To Be Known As The Innovative Therapies For World’s Leading Company In Market Unmet Medical Needs Expansion Services With A Focus On Asia

History History Company Profile 2016 Korean subsidiary basis Company Profile 2016 Korean subsidiary basis

1986 Spun off from History of Korea corporate body Suite 1901 City Air Tower, 159-9 Samsung- 4th Floor Sunghwan Bldg, 156, Dogok-ro, Company Celgene co. Address Celanese Company DKSH Korea, Ltd. Address 1989 Establish the Korea dong, Gangnam-gu, Seoul, Korea 2003 Took over stem Gangnam-gu, Seoul, Korea corporate body. President Taejin Ham Headquarters USA cell company 1999 Separation of Logistic President Matthew James Beebar Headquarters Zurich, Switzerland Business Unit ‘Antrhogenesis’ KRW 36.8 billion(Based on Corporate income 2004 Change the company Website www.celgene.com Annual Sales 2009 Started Celgene Icheon Center, West Icheon Center, tax return in 2016) Website www.dksh.com Branches name to DKSH Korea, business in Korea Gimpo Center Ltd. Telephone 02-3469-7800 2013 Transferred Abraxane 2008 Introduction of SAP Telephone 02-2192-9500 2014 Launched Revlimid 2013 Merger of Mirae Care with reimbursement Company 2015 Operation start of WIDC 2015 Approval of Pomalyst Start OTC sales in Korea Start ETC sales Employment Product 2016 Launched Abraxane Employment with reimbursement in 424 MES(Market Expansion Service) Open 37 6 pancreatic cancer 2010 CIM service: 2017 Launched Revlimid Consignment Inventory with reimbursement Management 2010 3PL/4PL Service: Major R&D Status Particulars - ISO 9001 Pharmaceutical - ISO 13485 warehouse/ delivery Main Products •Vidaza: Myelodysplastic syndrome, Acute Myeloid Leukemia - KGSP(Korean Goods Supplying Practices) service 2013 GPO service (name/indications) •Thalidomide Celgene Cap: Multiple myeloma - GSDP(Good Storage Distribution Practices) - Business license approval of pharmaceutical products, Medical Devices, •Revlimid Cap: Multiple myeloma Cosmetics and Health functional foods VAS(Value Added Service) Open - CGMP(Current Good Manufacturing Practice) for redressing & serialization •Pomalyst Cap: Multiple myeloma - DC space(in sqm): 70,000 2015 RA service(Registration) 2015 Serialization and •Abraxane®: Breast Cancer, Pancreatic cancer, Non-small cell lung cancer Major CSR Activities •‘Right to Play’ Aggregation service - Right to Play aims for the holistic development of children and youth in selected schools, youth 2015 Business license Major R&D Status Clinical Trials centers and surrounding communities by using sport and play-based learning activities. approval of Total 78 projects with 50 medical professionals and 247 patients - This program is carried out in collaboration with the Thai Minis try of Education and the Ministry pharmaceutical of Justice. products, Medical •DKSH-CCC funfair Devices, Cosmetics and Major CSR Activities •Support costs for treating Myelodysplastic syndrome Money raised during the DKSH’s Customer Care Center(CCC) was donated to the Princess Health functional foods Supported 65 million won Mother's Medical Volunteer Foundation to purchase medical devices. •Fantree Scholarship • - The Fantree Scholarship was established in response to the Great East Japan earthquake and Education program for blood cancer patients tsunami of March 2011 and is awarded to students orphaned by the disaster who need assistance Provide support for education program on understanding of diseases to continue their education. - The fund was contributed to by business partners and employees from around the world, with all and treatment to patients with Multiple myeloma and Myelodysplastic donations matched by the DKSH Group. syndrome and their families - To date, seven of the students have entered university and three are currently in high school. •Fantree Club-Alladin charity, etc - Alladdin Charity: raising funds for welfare homes for the elderly and underprivileged children in Malaysia(2014) - Donate Christmas present: donating Christmas presents to disadvantaged children in Taiwan(2014) - Sponsor a rugby day: sponsoring a rugby day with disadvantaged and disabled children in Cambodia(2014)

Directory - Prepare and distribute food: preparing and distributing food to the needy in Hong Kong(2014) Directory •Managing Korean Corporation(Executives of Healthcare) - Participate in Love Briquette Movement, delivering briquettes program to neighbor in need of Seoul Briquette Bank in December 2015 - Paper the cell for Jjokppangchon, the slurbs consisting of tiny rooms, located in Yeongdeungpo in May 2016 - On 4th November, 2016, we visited the local Holt Child Welfare Foundation and volunteered for the disabled and facilities •Mutual Cooperation - Hanmi pharm-SamChunDang Pharm-Ajinomoto Pharmaceuticals-Daewon Pharm 56 2017 KRPIA Annual Report - Il-Yang pharm 2017 KRPIA Annual Report 57 GE Healthcare Genzyme Korea Korea Co., Ltd Company That Continuously Develops And Keeps Advancing As A Pioneer Imagination at Work Of The Treatment Of Rare Disease

History History Company Profile 2016 Korean subsidiary basis Company Profile 2016 Korean subsidiary basis 1984 Established GE 1981 Established Genzyme 7F POBA Gangnam Tower, 343 Hakdong-ro, 235 Banpo-daero, Seocho-gu, Seoul, Company GE Healthcare Korea Address Samsung Medical Company Genzyme Korea Co., Ltd Address Corporation Gangnam-gu, Seoul, Korea Equipment Korea 1998 Established subsidiary President Francis Van Parys Headquarters Chicago, USA 1993 Equity change in joint President Hee-Kyung(Christine) Park Headquarters USA in Korea venture and business 2011 Integrated with Sanofi Website www.gehealthcare.co.kr Seoul, DaeJeon, Daegu, Pusan, Kwangju name to ‘Samsung GE Website www.sanofi.co.kr Annual Sales about KRW 86 billion Group Branches office, GEUK(SeongNam), APAC Fast Trak Healthcare’ Telephone 02-2136-9000 Telephone 02-6201-3114 center in Songdo 2001 Changed name of the company to GE Medical System Korea 2004 Acquired Amersham of GE Medical Systems Employment Product R&D Investment Employment R&D Investment 2005 Changed name of the company to GE 53 17 about 1.5 561 1 USD: billion Healthcare Korea KRW: billion (Based on Global HQ) 2014 Expansion with completion of GE Ultrasound Korea 2016 Opened APAC Fast Trak Center in Songdo • : An adjunctive diagnostic tool for serum thyroglobulin(Tg) Main Products •Visipaque: Contrast enhancement for computed tomographic head and body Main Products Thyrogen testing with or without radioiodine imaging in the follow-up of patients (name/indications) imaging. Angiocardiography- peripheral arteriography, cerebral arteriography, (name/indications) oronary arteriography, abdominal angiography with well-differentiated thyroid cancer who have previously undergone •Omnipaque: Contrast enhancement for computed tomographic. thyroidectomy. angiography(ventriculography, selective coronary arteriography), urography, myelography, other indications;Arthrography, ERCP/ERP, hysterosalpingography, •Cerezyme·Cerdelga: Type 1 Gaucher disease gastrointestinal series etc. •Fabrazyme: Fabry disease •Sonazoid: For ultrasound imaging associated with the following: Focal liver lesions •Aldurazyme: Mucopolysaccharidosis •Omniscan: For use in MRI to visualize lesions with abnormal vascularity(or those •Myozyme: Pompe disease thought to cause abnormalities in the blood-brain barrier) in the brain(intracranial •Aubagio·Lemtrada: Multiple sclerosis lesions), spine, and associated tissues, including MR Angiography

Major R&D Status Clinical Trials Major R&D Status Clinical Trials Total 9 projects in 29 institutions with 87 medical professionals and 3,640 patients Total 16 projects in 114 institutions with 602 medical professionals and R&D Pipeline Contrast media, Molecular imaging agents etc 917 patients Particulars R&D Pipeline Globally, 54 studies related publications in 2016 - FAP(Familial Amyloidosis Polyneuropathy, Phase 3 trials) - Pompe Disease(Phase 3 trials) Major CSR Activities •GE-WISET Global Mentoring Program MOU with WISET( Women In Science, Engineering and Technology), Developing Women in Science, Engineering and Technology by providing programs for Awards - Received EURORDIS Company Award as a leader in developing and improving leadership capabilities providing treatments for rare diseases(2013) •GE Sports Leadership Camp - Selected as Genetic Disease Foundation’s Industry Person of the GE held the GE Sports Leadership Camp, leveraging its curriculum from GE Year(2013) Crotonville leadership program, for 70 national athletes and coaches from the - Rare Disease Day Celebration, 2015 6 minutes walking campaign <2015 Directory Korea Ski Association(KSA) on May 10th. GE, as the official sponsor of the Korea Ski Directory Association, provides not only financial support, but also technological support and Korea CSR Film Festival> Ministry of Health and Welfare Award(2015) leadership development opportunities. •Training program for Bio talents MOU with several university, college, and specialized high school to develop future talents in bio industry and provide training program for them

58 2017 KRPIA Annual Report 2017 KRPIA Annual Report 59 Gilead Sciences GSK Korea Korea The Most Scientific, Ethical To help people do more, And Patient-Oriented Company feel better and live longer

History History Company Profile 2016 Korean subsidiary basis Company Profile 2016 Korean subsidiary basis 1987 Founded Gilead 1715 Established Plough 15F, Center 1 Bldg(West)., 26 Eulji-ro 9F LS Yongsan Tower, 191 Hangang-ro Company Gilead Sciences Korea Address 2001 Viread® approved Company GSK Korea Address Court Pharmacy in the UK 5-gil, Jung-gu, Seoul, Korea 2002 Tamiflu® and Hepsera® 92,Yongsan-gu, Seoul, Korea 1830 Established John K. President Paul Lee Headquarters USA approved President Hong Yoo-seok Headquarters UK Smith Pharmacy in 2011 Established Gilead Philadelphia, US Website www.gilead.co.kr Annual Sales about KRW 271.4 billion Sciences Korea Website www.gsk-korea.co.kr Branches Daejeon, Daegu, Gwangju, Busan 1942 Glaxo commercialized Penicillin for the first 2012 Released Truvada®, time Telephone 02-6030-3300 ® Telephone 02-709-4114 Annual Sales about KRW 301 billion Viread in Korea 1986 Established ‘Glaxo 2014 Released Stribild® in Korea’, a 50:50 joint Korea venture between UK-based Glaxo and 2016 Released Sovaldi and a pharmaceutical Harvoni in Korea Employment Product R&D Investment company in Korea Employment Product R&D Investment 2017 Released Genvoya and 1991 SmithKline Beecham Descovy in Korea 488 135 about 20 established a subsidiary 64 10 about 2 in Korea KRW: billion KRW: trillion 2000 Glaxo Wellcome (Based on Korean merged with SmithKline (Based on Global HQ) subsidiary) Beecham and established Glaxo SmithKline(GSK) PLC • : Asthma, COPD 2009 Took over a ® Main Products Anoro Ellipta/ Incruse Ellipta/ Relvar Ellipta Main Products •Viread : Chronic hepatitis B, HIV-1 •Fluarix Tetra: Influenza vaccine dermatology company ® (name/indications) (name/indications) •Stribild : HIV-1 •Triumeq/ Tivicay: HIV/ AIDS ‘Stiefel’; established •Cervarix: Cervical cancer vaccine ‘ViiV Healthcare,’ a joint ® •Truvada : HIV-1 •Synflorix: Streptococcus pneumoniae vaccine venture with Pfizer in • : Rotavirus vaccine • ®: Systemic fungal infection, Fever of unknown origin, Rotarix AIDS treatments AmBisome •Menveo: Meningitis vaccine 2010 Equity investment in Leishmaniasis •Avodart: Prostatic hyperplasia, Alopecia Donga Group •Sovaldi, Harvoni: Chronic HCV Major R&D Status Clinical Trials underway 2015 Took over the vaccine •Genvoya: HIV-1 infection Total 65 projects in 390 institutions with about 800 medical professionals and about 7,600 patients business of Novartis • : HIV-1 infection R&D Pipeline and established a joint Descovy 200/10mg and 200/25mg Vaccine(Ebola, Zoster), Respiratory diseases(Asthma, COPD), HIV/AIDS, Rare disease(Lupus), venture ‘GSK Consumer •Vemlidy: Chronic hepatitis B Cardiovascular disease(Myocardial infarction, Chronic heart disease, Anemia) Healthcare’ Particulars 2016 Established ‘Gavani - Ranked 1st in Access to Medicine Index among 20 global pharmaceutical companies Clinical Trials Bioelectronics’ in Major R&D Status (5 times in a row) partnership with Total 31 projects in 226 institutions with 407 medical professionals and 544 - Korea has been selected by GSK Group as one of the 20 R&D Foot Print Countries and plays a Google’s Verily Life key role across all stages of GSK's global clinical development programmes from an early phase Science patients - Conducting the First Trial in Patient studies on cancer epigenetics with local research institutes R&D Pipeline Antivirus(HIV/AIDS, hepatitis B, hepatitis C), Inflammatory disease, Major CSR Activities •Orange United Campaign - Movement for saving 1 million children in the poorest countries including local children in need, Respiratory disease, Cancer in partnership with Save the Children from 2013 - Various charity fund-raising including the 10% Benefit Sharing programme at the internal • shopping mall, employee's volunteering activities and the company's matching grants Major CSR Support for HIV/AIDS prevention, diagnosis, and education - Integrating the fund raised through employees' salary donation and the company's matching Activities program grants that started from 2009 - Received the Minister of Health and Welfare Award at the 4th Korea Sharing People Grand Prize Aims at early discovery of infectees, early treatment and reduction of in 2015 infection rate •Trek for Kids - A global campaign initiated by the Orange United that gives opportunity to take part in 8 day •Support for HIV patients and its supporting groups trekking to the Mount Kenya and community service in Africa - A GSK Korea employee participated in the event, raising more than 8m KRW thru voluntary Directory •Visiting health check-up for multicultural family activities at Seoul office Directory Support health check-up and prevention for underprivileged multicultural •Orange Day programme families - Our employees provide volunteering services to local communities on a selected working day - Hold an annual event of making kimchi for low-income families via voluntary services of our •Hope Gallery employees and executives •GSK Hope Concert Charity auction of art works created based on themes of experiences in CSR event that started first from 2000 to 2015 to raise social interest in and give hope to fighting against disease written by liver disease patients underprivileged people such as patients, and low-income and North Korean children •Support patients with lupus Patronize society of patients with lupus, which is a rare disease 60 2017 KRPIA Annual Report 2017 KRPIA Annual Report 61 Guerbet Imaging Solutions Korea Ltd. Korea A Leading Company Of Contrast Media A Leading Company Of Contrast Media That Supplies Cutting-edge Innovative That Supplies Cutting-edge Innovative Solutions In Imaging Diagnosis Area Solutions In Imaging Diagnosis Area

History History Company Profile 2016 Korean subsidiary basis Company Profile 2016 Korean subsidiary basis 1901 Marcel Guerbet 1887 Established 6F IS Bldg., 10, Teheran-ro 38 gil, The 6th F/L, IS Building, 10, Teheran-ro Company Guerbet Korea Address developed Lipiodol® Company Imaging Solutions Korea Ltd. Address Mallinckrodt Gangnam-gu, Seoul, Korea 1926 Established André 38gil, Gangnam-gu, Seoul, Korea 2000 Merged by Tyco President Mathieu Elie Albert Raymond Headquarters France Geurbet and Co. President Mathieu Elie Albert Raymond Headquarters France International Laboratory 2007 Separated as Website www.guerbet.co.kr Branches Seoul 1989 Launched Dotarem®, a Website www.guerbet.co.kr Branches Seoul Covidien from Tyco contrast media for MRI International Telephone 02-3453-1212 Annual Sales KRW 31.9 billion Telephone 02-3404-2000 Annual Sales KRW 19.2 billion 1994 Launched Xenetix®, 2013 Established a contrast media for Mallinckrodt Korea X-ray 2015 Was acquired by 1998 Established Guerbet Guerbet Korea Korea 2017 Changed name of Employment Product R&D Investment 2011 Launched Scanbag company as Imaging 2014 Launched a newest Employment Product Solutions Korea Ltd. 45 8 about 53.38 injector Flowsens 2015 Acquired Mallinckrodt 3 6 EUR: million (Based on Global HQ) Korea Inc

Main Products •Xenetix®: Contrast media for X-ray Main Products Contra Media (name/indications) •Dotarem®: Contrast media for MRI (name/indications) - Optiray: Contrast Media for CT & Angiography •Lipiodol®: Transcatheter arterial chemoembolization •Flowsens: Injector Injector Delivery System - CT9000 Adv: Contrast Media delivery system for CT Major R&D Status Clinical Trials - Optione: Contrast Media delivery system for CT Total 4 projects(3 global and 1 local) in 19 institutions with 80~90 - Optivantage DH: Contrast Media delivery system for CT medical professionals and 550 patients - Angiomat illumena: Contrast media injector for Angiography - Optistar Elite: Contrast Media delivery system for MRI R&D Pipeline Contrast media for CT & Cath lab and MRI, Interventional Radiology & Theranostics, Imaging Solution and Service Main Disease - Cardiovascular disease - Cancer - Inflammatory disease - Nerve disease

Major CSR •Tree Planting Program Activities Conducted tree-planting activities at Noeul Park on occasion of Arbor Day •A coal briquette event Directory Give briquette for love Directory

62 2017 KRPIA Annual Report 2017 KRPIA Annual Report 63 Ipsen Korea Janssen

Ltd. Korea Janssen Korea, Innovation For Patient Care Innovative And Responsible

History History Company Profile 2016 Korean subsidiary basis Company Profile 2016 Korean subsidiary basis 1998 Established Beaufour 1983 Established as the #11fl, Kamco tower, 262, Gangnam- 25,26F LS-Yongsan Tower, 92 Hangang- Company Ipsen Korea Ltd. Address Ipsen Korea Company Janssen Korea Address pharmaceuticals division of daero, Gangnam-gu, Seoul, Korea 1999 Released Botulinum daero, Yongsan-gu, Seoul, Korea Johnson&Johnson President Kim, Min-Young Headquarters France Toxin A Dysport President Kim Oak-Yeon, Lee Jung-Hee Headquarters USA Korea corporation and 2001 Released Diphereline constructed Hyangnam Website www.ipsen.kr Annual Sales about KRW 12 billion Injection 3.75mg Head office in Seoul, 1 plant(Hyangnam, plant Gyeonggi province) and 7 branches 1990 Ranked No.1 in 2004 Released Somatuline Website www.janssen.com/korea Branches Telephone 02-405-9500 (Northern Seoul, Southern Seoul, Suwon, pharmaceutical 2005 Changed name of Daejeon, Daegu, Busan and Gwangju) company productivity(5 company as Korea years in a row) Ipsen Ltd. Telephone 02-2094-4500 Annual Sales about KRW 245.3 billion 1991 Awarded Global Janssen Group Released Diphereline Excellence Award Injection 11.25mg 1994 Ranked No.1 in sales Employment Product R&D Investment 2013 Changed name of of joint company and company as Ipsen No.1 for 2 consecutive years in net profit Korea Ltd. 25 6 about 611 Employment Product R&D Investment of pharmaceutical KRW: million company about 1999 Achieved the first 486 42 17 approval for ISO 14001 KRW: billion in the world 2007 Received citation for monitoring drug adverse reaction from Main Products •Somatuline: Acromegaly, gastroenteropancreatic neuroendocrine the MFDS(3years in • : Schizophrenia (name/indications) tumors(GEP-NET), Main Products Invega Sustenna a row) •Sirturo: Multi-drug-resistant tuberculosis(MDR-TB) 2011 Awarded ‘Social symptom of carcinoid syndrome (name/indications) •Velcade: Multiple Myeloma Benefactor Award’ – •Stelara: Psoriasis, Psoriatic Arthritis •Diphereline: Prostate cancer, central precocious puberty, Social Welfare •Imbruvica: Mantle Cell Lymphoma endometriosis, uterine fibroids •Ultracet: Moderate to severe Pain Corporations in Seoul Awarded ‘Excellence •Dysport: Cervical dystonia, upper limb spasticity, blepharospasm, •Simponi: Rheumatoid Arthritis, Ankylosing Spondylitis 2013 •Remicade: Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Ulcerative Colitis Award in Relationship hemifacial spasm, glabella line, cerebral palsy with Local Community’ Major R&D Status Clinical Trials – KoreaPR Total 65 projects in 400 institutions with 1,600 medical professionals and 3,600 patients 2014 Awarded grand prize in local community for R&D Pipeline Major R&D Status Clinical Trials - Cardiovascular(Heart failure, Depression), Oncology(Hematology, Prostate Cancer), Infectious Korea PR 2015 Selected as the partner Total 4 projects in 12 institutions with 18 medical professionals and 103 Diseases(Hepatitis, Respiratory Infection), Immunology(Inflammatory Bowel Disease, Psoriasis, Rheumatoid Arthritis, Ankylosing Spondylitis) company with the patients most outstanding Particulars cooperation from - One of 31 pivotal country operations for global clinical operations under Janssen R&D, LLC and one of 11 core countries which conducts early-phase development STOP-TB Partnership - Agreed a MOU with Ministry of Health and Welfare in 2014 and started direct and indirect Korea Major CSR •Support for patients with acromegaly since 2002 investment over next 5 years(2014~2018) in R&D, Expansion and development of scientific Activities •Support for ‘Day of People with Disability’ exchange and collaboration programs for cancers, autoimmune diseases and severe infectious diseases, such as MDR-TB, HIV and hepatitis C Medicine Donations: Botulinum Toxin donations for patients with - Aim for open innovation with numerous local partners including consignment of cooperative cerebral palsy R&D program of Johnson&Johnson Innovation center with KDDF in 2015 - Seoul Metropolitan Government, Korea Health Industry Development Institute(KHIDI) signed a Memorandum of Understanding(MOU) in 2017, with representatives of Johnson & Johnson Innovation, Johnson & Johnson Medical Devices Companies and Janssen Korea to form a strategic alliance to identify promising universities, companies, and startups and help them to accelerate early-stage technological innovation by strengthening the network between

Directory scientists, biotech firms, and investors. Directory

Major CSR •Paul Janssen Scholarship - To provide financial and emotional support for teenagers whose family members suffer from Activities mental diseases - Operate college students mentoring group to provide emotional support to the teenagers •Peace in Mind - Helping that patients with schizophrenia overcome social prejudice and return to society. - Volunteering with 'SROLANH' and ‘Taiwha Fountain House’(vocational rehabilitation facility for patients with mental disorders) 64 2017 KRPIA Annual Report 2017 KRPIA Annual Report 65 Johnson & LEO Pharma Johnson S&D Korea LLC. Caring For The World, We Help People Achieve Based On Our Credo Healthy Skin

History History Company Profile 2016 Korean subsidiary basis Company Profile 2016 Korean subsidiary basis 1983 Approval of a joint 1908 Pharmacists Anton LS-Yongsan Tower, 92 Hangang Daero, 17F Seoul City Tower Bldg., 110, Huam- Company Johnson & Johnson S&D LLC. Address venture by the Company LEO Pharma Korea Address Antons & August Yongsan-gu, Seoul, Korea Ministry of Finance ro, Jung-gu, Seoul, Korea Kongsted established President Kim Kwangho Headquarters USA Make registration President Jihyun Kim Headquarters Denmark LEO Pharma of incorporation as 1923 Produced insulin Website www.jnj.com Annual Sales about KRW 3.7 billion Johnson&Johnson Website www.leo-pharma.kr Annual Sales about KRW 12 billion 2008 Launched Xamiol®, Korea Corp. celebrated the 100th Telephone 02-2094-3000 Telephone 02-771-1110 1984 Begin business anniversary of LEO activities(Johnson's Pharma Baby brand) 2009 Implemented New global strategy of LEO Pharma(‘Going to Employment Product Employment Product R&D Investment Gold–step by step’), Acquired Peplin Inc., 118 12 42 6 about 224.1 Australian-based KRW: billion US Biotechnology (Based on Global HQ) company 2011 Entered into Korea market 2011 Launched LEO Main Products •Xamiol®: Psoriasis Pharma in Korea Main Products •Tylenol: fever, pain and headache•Fluarix Tetra (name/indications) •Daivobet®: Psoriasis 2013 Established LEO (name/indications) •Nizoral: dandruff, seborrheic dermatitis, and leucoderma •Daivonex®: Psoriasis Pharma Korea •Nicorette: adjuvant therapy againist smoking ® •Picato® gel: Actinic keratosis 2014 Launched Picato gel •Protopic®: Atopic dermatitis(Marketing authorization holder is Astellas 2016 Transfer Astellas’ Major R&D Status •Making Wish Bear Korea. LEO Pharma Limted for Exclusive Sales Promotion rights.) global dermatology - Make a Wish Bear with 'MAKE A WISH' Foundation which cheers up business to LEO pediatric patients who suffer from rare disease Pharma •Love Eye Campaign 2016 Started Exclusive - Under the slogan "Please protect children's eye", this campaign tries to Major R&D Status R&D Pipeline Sales Promotion of ® make bright and healthy future for children by protecting our children's - Actinic keratosis Protopic eyes against environment which damages the eyes - Psoriasis - Skin diseases(Eczema, Atopic dermatitis) •Peace in Mind - Helping that patients with schizophrenia overcome social prejudice and return to society. • - Volunteering with 'SROLANH' and ‘Taiwha Fountain House’(vocational Major CSR Activities Community Service at a local soup kitchen Helped out at a local soup kitchen for homeless people rehabilitation facility for patients with mental disorders) •J&J family Afforestation - Practice the love of the environment through 'J&J Family Forest' caring and tree planting - Visiting Holt Children's Services Inc. to execute volunteering like cleaning, taking a walk, taking a bath, etc. Directory Directory

66 2017 KRPIA Annual Report 2017 KRPIA Annual Report 67 Lilly Korea Lundbeck Lilly Unites Caring With Discovery Korea Lundbeck strives for global leadership To Make Life Better For People in psychiatry and neurology by Around The World improving the lives of patients.

History History Company Profile 2016 Korean subsidiary basis Company Profile 2016 Korean subsidiary basis 1876 Established Eli Lilly 2002 Established Lundbeck 4F LG Seoul Station Building, 98 Huam- 19F, Olympic-ro 35-gil 137, Songpa-gu, Company Lilly Korea Address 1923 Launched the first Company Lundbeck Korea Address Korea ro, Jung-gu, Seoul, Korea insulin in the world Seoul, Korea 2004 Released Ebixa President Paul Henry Huibers Headquarters USA 1943 Mass production of President Herman Santoni Ramos Headquarters Denmark 2006 Released Lexapro antibiotics Penicillin 2007 Selected Lundbeck Website www.lilly.co.kr Branches Daejeon, Busan 1982 Established Daewoong Website www.lundbeck.co.kr Annual Sales about KRW 43.2 billion Best Business Lilly Achievement Telephone 02-3459-2600 Annual Sales about KRW 146 billion Telephone 02-431-6600 1998 Inaugurated Lilly Korea 2008 -Lexapro generated 2011 Selected as a family KRW 20 billion in ~2019 friendly company by annual sales for the the Ministry of Gender first time among Equality and Family antidepressants Employment Product R&D Investment 2012 Awarded Minister Employment Product R&D Investment -Announced as the prize in recognition person and company 256 16 about 5.2 of eradicating 70 4 about 2,967 of the year in KRW: Billion tuberculosis DKK: Million December, 2008 (Based on Global HQ) 2017 Recognized as one (Based on Global HQ) 2010 Co-marketing of of the World’s Most Ebixa with Hanmi Ethical Companies by Held Lundbeck Asia Main Products •Trulicity: Adults with type 2 diabetes mellitus Ethisphere Institute Symposium in Korea •Alimta: Locally advanced or metastatic nonsquamous non-small cell lung cancer 2012 10th anniversary of (name/indications) •Lartruvo: Soft tissue Sarcoma Main Products •Lexapro: Major depressive disorder, Panic disorder, Social anxiety foundation •Cymbalta: Major depressive disorder, Generalized anxiety disorder, Diabetic peripheral neuropathic (name/indications) disorder, Generalized anxiety disorder, Obsessive compulsive disorder pain, Fibromyalgia 2013 Co-marketing of • : Alzheimer’s disease •Humalog, Humulin, Basaglar: Adult and pediatric patients with diabetes mellitus Ebixa Lexapro with Jeil •Cyramza: Advanced gastric or gastro-esophageal junction adenocarcinoma •Azilect: Idiopathic Parkinson's disease Pharmaceutical •Forsteo: Osteoporosis •Brintellix: Major depressive disorder 2014 Released •Zyprexa: Schizophrenia, bipolar I disorder •Cialis: Erectile dysfunction, The signs and symptoms of benign prostatic hyperplasia Azilect(2014.07) 2015 Released Major R&D Status Clinical Trials Total 45 projects in about 300 institutions with 1,000 medical professionals and about 2,500 patients Brintellix(2015.11) Major R&D Status Clinical Trials R&D Pipeline Oncology, Diabetes, Autoimmune diseases, Alzheimer’s disease, Pain Total 4 projects in 85 institutions with about 260 medical professionals Particulars and about 1,800 patients - Ranked 1st in number of IND approval in 2011 and 2016(Based on announcement of MFDS) - Eli Lilly and Hanmi Pharmaceutical Co., Ltd. have entered into an exclusive R&D Pipeline license and collaboration agreement for the development and commercialization CNS disease: Depression, Dementia, Schizophrenia of HM71224, for the treatment of autoimmune and other diseases - Agreement with the Korea Research Institute of Chemical Technology through the Open Innovation Drug Discovery Program • - Collaboration Academy with Seoul Bio Hub co-hosted by Seoul Metropolitan Major CSR Activities Senior Day Care Centre in Songpa District Government and KHIDI Donate and support the rehabilitation activities for the elderly in local community. Major CSR •Global Day of Service To mark 10-year of Lilly Global Day of Service, Lilly Korea employees visited 8 Social Welfare •Employee Volunteering(OTCAN) Activities Organizations in needed. Lilly employees have now volunteered more than 1 million hours to complete more than 4,000 projects in 65 countries. Support children in the 3rd world countries by providing old clothes •Connecting Hearts Abroad •Collaboration New CSR activity launched in 2011 that selected 100 employees as ‘CHA ambassador’ volunteer in 8

Directory - Lundbeck · Jeil: Lexapro Directory developing countries during 2 weeks. From 2011 to 2017, 11 employees of Lilly Korea participated in the project. - Lundbeck · Teva: Azilect •World Cancer Prevention Month Event & Donation To promote the prevention and social attention of gastric cancer, Lilly Korea’s employees shared low-salt breakfasts and participated in donation in celebration of World Cancer Prevention Month. The funds were delivered to the Social Welfare Organization Community Chest of Korea by adding a matching grant of Lilly Korea.

68 2017 KRPIA Annual Report 2017 KRPIA Annual Report 69 A. Menarini Merck Ltd. Korea/ Biopharma Korea Ltd. Healthcare Brand That Leads Improvement Of Quality Of Life In Division Merck – A Leading Science Asia Pacific Region and Technology Company

History History Company Profile 2016 Korean subsidiary basis Company Profile 2016 Korean subsidiary basis 1886 Established Menarini 1985 EMEDIA launched business 12F Seongdam Bldg., 411, Teheran-ro, Merck Ltd. Korea/ Biopharma 4F Haesung 2 Bldg, 508 Teheran-ro, as Merck’s branch in Korea 1915 Moved headquarters Company Address Company A. Menarini Korea Ltd. Address Division Gangnam-gu, Seoul, Korea 1989 Merck registered as a Gangnam-gu, Seoul, Korea to Firenze, Italy corporation Managing Director & Representative 1999 Organized Merck drug President Kim Albert Chan-Wook Headquarters Italy 1964 Opened a laboratory in President Director: Glenn Young/ Headquarters Germany business unit Barcelona, Spain 2001 Launched Concor®, a General Manager: Dr. Uloff Muenster Website www.menariniapac.co.kr Annual Sales KRW 53.6 billion 1992 Entered central treatment of cardiovascular diseases European market by Head office in Seoul and 4 branches(Daejeon, ® Telephone 02-2037-7300 Website www.merck.co.kr Branches 2003 Launched Glucovance , a acquiring Berlin- Daegu, Busan and Gwangju) diabetic treatment 2004 Launched Glucophage®, an Chemie Telephone 02-2185-3800 oral hypoglycemic agent 2003 Opened Menarini 2006 Erbitux® registered in Korea Biotech 2007 Completed integration between Merck and Serono 2011 Entered Asia Pacific 2008 Launched Easypod, an market by acquiring injector of Saizen® Employment Product 2009 Concluded MOUs with the Invida Group Green Cross and Samsung 2013 Launched Menarini Employment Product R&D Investment Medical Center 107 23 2011 Conducted Wish Mom Korea(March) Campaign for improving 139 29 about 2 infertility jointly with the (Merck Ltd. Korea EUR: billion Ministry of Health and Welfare and Seoul city Biopharma Division) (Based on Global HQ) government and established ‘Korean Cancer Association- Main Products •Abstral sublingual: Breakthrough cancer pain Merck Scientific Award’ 2012 Established ‘Korean Cancer (name/indications) •Priligy Tab: Premature ejaculation Main Products •Erbitux®: Metastatic colorectal cancer and Relapsing and Metastatic head and neck Association-Merck Scientific •Nebilet Tab: Hypertension, Chronic heart failure cancer Award’ (name/indications) •Gonal-F®: Infertility(Follicle Stimulating Hormone) 2013 Established ‘Korean Society •Vancocin-CP for Inj: Antibiotic for injection •Rebif®: Multiple sclerosis for Reproductive Medicine- • : Onychomychosis •Saizen®: Hormone Deficiency Merck Scientific Award’ Fulcare Nail Lacquer 2014 Risk Sharing Agreement of •Concor®: Hypertension, Angina pectoris and Chronic heart failure • : Hypertrophic and keloidal scar, treatment for Cicatrix Erbitux allowing access to Dermatix Ultra Gel • ® : Type 2 Diabetes Glucophage XR colorectal cancer patients 2014 Established Rovatitan® Major CSR •Smile Asia Major R&D Status Clinical Trials alliance with LG Life Total 20 projects in 111 institutions with 100 medical professionals and about 2,147 patients Sciences, a Hypertension & Activities As "Menarini" continue to promote CSR work in the region and support Hyperlipidemia treatment Smile Asia*, Menarini volunteer group will join the upcoming Medical R&D Pipeline 2017 60 years of clinical More than 10 including Liver cancer, Lung cancer, Colorectal cancer, etc experiences with Missions organized by Smile Asia. Glucophage 2017 Established a Concor®, *Smile Asia is a charity dedicated to providing life-transforming treatment to •Korean Cancer Association-Merck Scientific Award Major CSR Activities Glucophage® and children with cleft lips, cleft palates and other facial deformities. The award to encourage academic research activities in colorectal cancer and head and Glucophage XR® alliance neck cancer and contribute to development of oncology medical science in Korea under with YungJin Pharm •Menarini Korea’s brand ‘Fulcare’ holds campaign to raise funds to partnership with the Korean Cancer Association established in 2011 help single mom and patient who suffer from lupus erythematosus. •Korean Association for Clinical Oncology-Merck Scientific Award Download the application 'Everyday Fulcare' or post a picture on this app The award to encourage clinical research in colorectal cancer and contribute to oncology research and development initiatives in Korea under partnership with the Korean will earn donation points and donate this point to single moms. Association for Clinical Oncology established in 2012 6,000 people participated 1st campaign in April and accumulated funds •Korean Society for Reproductive Medicine-Merck Scientific Award totaling 3million KRW were deposited and donated to the project to support The award to contribute to recognize scientific achievement and encourage technology the single mom of Good Neighbors’ Good Heart Center in June. development in the fertility research field under partnership with Korean Society for Reproductive Medicine established in 2013 And 2nd campaign in July, accumulated funds totaling 3million KRW were • donated to ‘Korea Lupus support group’ in Oct. ChildFund for unprivileged neighbors Directory Merck Biopharma supported cost of growth treatment for children in need with short Directory height with ChildFund •Donate Laptop to ‘Jumong Rehabilitation Center’ Menarini Korea donated 20 used laptops to ‘Jumong Rehabilitation Center’ •Briquette Delivery Volunteering Merck Employee and their family members participated in briquette delivery volunteering located in Sangil-dong, Gangdong-gu. activity and 5,200 briquettes were served for underprivileged neighbors in Korea Those laptops help them with on-line programs, working and others. Awards Received the exclusive Top Employer South Korea 2017 and Asia Pacific 2017 certificate by the Top Employers Institute

70 2017 KRPIA Annual Report 2017 KRPIA Annual Report 71 MSD Korea Mundipharma Ltd. To discover, develop and provide Korea Ltd. innovative products and services that save and improve lives around the world Bring More To Life

History History Company Profile 2016 Korean subsidiary basis Company Profile 2016 Korean subsidiary basis 1851 E. Christian Friedrich 1998 Established Mundipharma 23Fl Seoul Square Building 416, 3F Seoul Square, 416 Hangang-daero, Company MSD Korea Ltd. Address Shering started drug Company Mundipharma Korea Ltd. Address Korea Ltd. Hangang-daero, Jung-gu, Seoul development and sales Jung-gu, Seoul, Korea 1999 Launched Zytram® XL ® President Avi BenShoshan Headquarters USA 1891 Established Merck & Emerging Markets regional 2001 Launched Oxycontin President Luke(Myung Sea) Lee Headquarters Co. Inc. in USA office(Singapore) 10․20․40mg Website www.msd-korea.co.kr Branches Daejeon, Daegu, Gwangju and Busan 1987 Started , 5 branches including Korea headquarter 2012 Established Oncology & Telephone 02-331-2000 Annual Sales about KRW 612.4 billion Website www.mundipharma.co.kr Branches ever longest period office in Seoul Respiratory Business Unit program for one 2013 Launched Oxynorm® and product in history Telephone 02-568-5689 Lodotra® 1994 Established MSD Korea 2014 Launched Flutiform®, 2011 Received Prime Medifoam® ® Employment Product R&D Investment Minister’s citation 2015 - Medifoam , The Most for contributing to Trusted Brand Award 2017 ® 669 126 10.1 USD: Billion attracting foreigners’ - Launched RepiGel (Based on Global HQ) investments, on the Employment Product - License and asset Foreign Company Day purchase agreement for 2012 Received CSR Leader 239 21 ZEVALIN®(Ibritumomab of the year in the tiuxetan) category of Innovation 2016 - Exclusive sales contract Leadership from for Biosolution’s new Main Products •Keytruda: Non-Small Cell Lung Cancer, Melanoma Korea Management Keraheal-AlloTM(an (name/indications) •Gardasil & Gardasil9: HPV prevention vaccine Association Consulting, Main Products •Targin®: Pain-Relieve moderate to severe persistent pain allogeneic keratinocyte •Zostavax: Herpes zoster prevention vaccine Received ‘Certificate product) (name/indications) •Norspan®: Pain-Treatment of moderate, chronic non-malignant pain •Januvia: Diabetes of excellent family- - Recognized as ‘Aon •Gyno-betadine®: Feminine Care-Vaginitis •Atozet: Hyperlipidemia friendly company from Hewitt Best Employer- • ®: Asthma •Propecia: Alopecia Ministry of Gender Flutiform Korea 2016’ ® •Isentress: AIDS Equity and Family •Medifoam : Wound Care-Moist wound dressing 2016 Selected as ‘the best working place in Major CSR Activities “Bring Hope to Community” Major R&D Status Clinical Trials the pharmaceutical •Charity Donation Box Total about 59 projects in about 289 institutions with about 289 medical industry’ by Forbes Donations generated from fund raising contributed by employees for professionals and about 1,941 patients Korea pediatric cancer patients and their family R&D Pipeline •Donation for pediatric cancer patients and their family Diabetes, Anticancer, Hepatitis C, HIV, Alzheimer's disease, Antibiotics Donation to Korea Pediatric Cancer Foundation to support ‘emergent medical cost of living’ for pediatric cancer patients & their family Major CSR •Love in Action •“Hope” Flower Basket Activities Employees’ voluntary service for low-income families on 3rd Saturday Deliver the flower basket produced by employees of Mundipharma every month since 2008 Korea to the pediatric cancer patients and their family on the company foundation day Awards •Received Innovative Social Contribution Award from Korea Management Association(2012)

Directory •Selected as a Family Friendly Company by the Ministry of Gender Directory Awards •Recognized as ‘Aon Hewitt Best Employer-Korea 2016’ & ‘Best Equality & Family(2012) Workplace for Y generation in Korea(2016, Aon Hewitt)’ •Seoul Mayer’s Award for ‘Excellence in Public-Private Partnership’(2014) •Recognized 'Best workplace’ by Fortune Korea and Job Planet(2015) •Recognized as ‘Aon Hewitt Best Employer-Korea 2015’

72 2017 KRPIA Annual Report 2017 KRPIA Annual Report 73 Novartis Novo Nordisk Korea Ltd Pharma Korea To Discover New Ways To Improve Ltd. A Leader In Developing And Providing And Extend People’s Lives Cutting-edge Diabetic Treatments

History History Company Profile 2016 Korean subsidiary basis Company Profile 2016 Korean subsidiary basis 1983 Established 1994 Established Novo Nordisk 18F YONSEI Foundation Bldg., 10, Novo Nordisk Pharma Korea 137, Olympic-ro 35-gil, Songpa-gu, Company Novartis Korea Ltd Address Korea-Switzerland Company Address Pharma Korea Tongil-ro, Jung-gu, Seoul, Korea Pharmaceutical(a Ltd. Seoul, Korea 2004 Launched NovoMix® 30 Klaus Ribbe, Country joint venture between President Rana Azfar Zafar Headquarters Denmark in Korea President Headquarters Switzerland ® President a.i. Switzerland-based 2005 Launched NovoRapid in Ciba-Geigy and a Website www.novonordisk.co.kr Branches Daejeon, Daegu, Gwangju, Busan Korea Website www.novartis.co.kr Branches Daejeon, Gwangju, Busan, Daegu Korean company) 2007 Launched Levemir® in Telephone 02-2188-8900 Annual Sales KRW 85.2 billion 1986 Switzerland-based Korea Telephone 02-768-9000 Annual Sales KRW 448.4 billion Sandoz and Dongwha 2007 Moved office Pharmaceutical signed building(Korea AD Cultue a contract for a joint Center, Jamsil) investment 2011 Launched NovoSeven®RT Employment Product R&D Investment 1986 Established Sandoz in Korea Employment Product R&D Investment Korea 2012 Launched Victoza® in about 14.6 1996 Launched Ciba-Vision 110 16 Korea USD: Billion 492 about 100 9.0 Korea DKK: billion 2014 The 20th anniversary (Based on Global HQ) (Based on Global HQ) 1997 Launched Novartis 2015 Launched Tresiba® in Korea Korea 2006 Launched Sandoz 2017 Launched Ryzodeg® in Korea, a generics Main Products •Tresiba ®: Diabetes Korea •Entresto: Chronic Heart Failure Main Products company(a separate ® •Cosentyx: Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis (name/indications) •Ryzodeg : Diabetes (name/indications) •Glivec/Tasigna: Chronic Myeloid Leukemia corporation) •Victoza®: Type 2 Diabetes •Zykadia: ALK+ Metastatic Non-small Cell Lung Cancer 2007 Launched vaccine ® •Galvus: Diabetes Mellitus Type 2 •Novomix 30: Diabetes business division •Exforge: Hypertension •NovoRapid®: Diabetes •Lucentis: Neovascular(wet) age-related macular degeneration 2011 Integration with Alcon •NovoSeven® RT: Haemophilia Korea Major R&D Status Clinical Trials •Norditropin/Nordilet®: Growth Hormone Over 200 clinical trials for new molecular entities are underway, and more than 197 clinical trials 2015 Novartis-GSK have been conducted in Korea over the last 10 years Transaction(Acquisition R&D Pipeline of GSK Oncology, Cardiovascular(Acute and Chronic Heart Failure), Respiratory(Asthma, COPD), Infection/ creation of Consumer Immunology(Psoriasis, Rheumatoid Arthritis, Nonalcoholic steatohepatitis), Nueroscience(Multiple Major R&D Status •Clinical Trials Sclerosis, Migraine, Neuropathic Pain, Alzheimer’s Disease), Oncology(Immuno-Oncology, Lung Healthcare joint Project 6, Participating Institution 36, Participating Medical Professional Cancer, Breast Cancer, Blood Cancer, Melanoma, Renal Cell Carcinoma) venture, Sales of 137, Participating Patient 345 Particulars Vaccine business) - 16 major approvals in US, Europe and Japan in 2016 •R&D Pipeline - Global Drug Development(GDD) was established with over 23,000 professionals to - Diabetes, Obesity, Haemophilia, Growth Hormone oversee the new drug development •Particulars Major CSR •Novartis Community Partnership Day Various employee volunteering programs by celebrating anniversary of founding(April 24th) - The largest supporter of clinical trials of unapproved drugs used for Activities •‘CheerYou’ Program treating metabolism diseases. Emotional support program for patients in rare and orphan disease and families •‘GahwaMOMsaseong’ A number of programs for the emotional support of female cancer patients and their families conducted Major CSR Activities •Environment protection and improvement activities •Sponsorship of Korea-Swiss Life Science Symposium An annual event that government officials, industry and academia experts from both countries - Joined in project of disclosing information on carbon participated to establish a cooperative network in the field of life sciences - Optimized production processes and saved energy Directory Directory - Use of eco-friendly and renewable energies at facilities in Denmark Awards •Campaign of Discovering Five-generation Families Received Excellence Award in Corporate Image Segment of the Korea PR Awards(2007) •Changing Diabetes® Campaign •Organ Donation and Life-sharing Campaign Received Golden World Award in Social Contribution Segment from the International PR Association •Do-gather Campaign 2015 Happy+ Social Contribution Award by Korean Journalists Award and Korean Employers Association

74 2017 KRPIA Annual Report 2017 KRPIA Annual Report 75 ONO Pharma OXY Reckitt Korea Co., LTD. Benckiser LLC Dedicated to Man's Fight Our vision is a world where people are against Disease and Pain healthier and live better.

2016 Korean subsidiary basis History History Company Profile Company Profile 2016 Korean subsidiary basis 2013 Established ONO 1991 Established OXY B-13F, The-K Twin Towers, 50, 24F Two IFC 10, Gukjegeumyung-ro, Company ONO Pharma Korea Co., LTD. Address Pharma Korea Company OXY Reckitt Benckiser LLC Address 1994 Completed construction of Jong-ro 1-gil, Jongno-gu, Seoul 2015 KFDA approved Yeongdeungpo-gu, Seoul, Koreal plant in Iksan President Kunihiko Ito Headquarters Japan(Since 1717) ‘Opdivo’ for Melanoma President Park Dongsuk Headquarters The United Kingdom 1996 OXY Clean obtained the 2016 KFDA approved world’s first eco mark Website www.onopharma.co.kr Branches Seoul ‘Opdivo’ for Non-Small 1 branch each in Daejeon and Busan, 2001 Acquired OXY from Reckitt Website www.oxyrb.co.kr Branches Cell Lung Cancer(for and a plant in Iksan Benckiser Telephone 02-928-8423 Annual Sales KRW 2,500 billion the first time in Korea) 2005 Changed company’s name Telephone 02-421-6789 Annual Sales KRW 120 billion 2017 KFDA approved to ‘OXY Reckitt Benckiser’ expanded indication 2012 Launched Gaviscon and for 'Opdivo' as Strepsils in Korea treatment for, kidney Employment Product R&D Investment cancer, urothelial carcinoma cancer, 23 65 580 head and neck cancer, Employment Product (3 based on KRW: billion Hodgkin lymphoma Korean market) and combination 269 60 therapy with Yervoy for (2 based on Korean market) melanoma. Main Products •Opdivo: NSCLC(Non-Small Cell Lung Cancer), Melanoma (name/indications) •FOY: Pancreatitis, DIC-Disseminated intravascularcoagulation •Yervoy: Melanoma Main Products •Gaviscon: Stomach disorder (name/indications) •Strepsils: Laryngopharyngitis Major R&D Status Clinical Trials Project 39, Research Facilities 3, Indication NSCLC(Non-Small Cell Lung Cancer) Awards •Industry-best in Eight categories from Dow Jones Sustainability World R&D Pipeline index 2015 Nivolumab(Gastric Cancer, Urothelial Cancer, Small Cell Lung Cancer, Esophageal Cancer, Head and Neck Cancer, Hepatocellular Carcinoma, etc.) •Company of the Year in the British OTC industry •Forbes '100 most innovative companies'(One of the 5 UK businesses) Particulars •CDP Climate Disclosure Leader 2015, for the seventh consecutive year •Nivolumab for hepatocellular carcinoma: •Ranked No.4 in World's Top 10 Green Companies - Received approval for the second line treatment by the U.S. FDA in 2017 •Ranked No.7 in the Global Most Sustainable Corporations in the World - Received positive opinion recommending the approval by CHMP in 2017 Index •Nivolumab for metastatic colorectal cancer: •Received Product of the Year 2015 for product innovation Received priority review by the U.S. FDA in 2017 •Dettol and Lysol's handwash system received Gold in Product design in •Nivolumab for urothelial carcinoma(UC) the DBA(Design Business Association) Design Effectiveness Awards Received approval for the second line treatment by the U.S. FDA and The European •Winner in Health and Household of Britain's most admired companies commission(EC) in 2017 •2nd in the 2016 Global 500 Newsweek Green Ranking •Nivolumab for squamous cell carcinoma of the head and neck(SCCHN): •Dow Jones Sustainability index, RB scored 83 out of 100, and finished Received approval by The European commission(EC) in 2017 industry-best in eight categories. •Nivolumab and ipilimumab combination for melanoma: •CDP Climate Disclosure Leader 2016 Received approval for the first-line treatment by the U.S. FDA in 2016

Directory •Nivolumab for classical hodgkin lymphoma(cHL): Directory Received accelerated approval designation by the U.S. FDA in 2016

•Nivolumab for urothelial carcinoma(UC) and squamous cell carcinoma of the head and neck(SCCHN): Received breakthrough therapy designation by the U.S. FDA in 2016

76 2017 KRPIA Annual Report 2017 KRPIA Annual Report 77 Pfizer Roche Korea Pharmaceuticals Co., Ltd. Korea Ltd. Working Together For A Doing Now What Patients Healthier World Need Next

2016 Korean subsidiary basis History History Company Profile Company Profile 2016 Korean subsidiary basis 1849 Established the 1896 Established Roche group Pfizer Pharmaceuticals Pfizer Tower, 1-11 Hoehyeon-dong 3-ga, 17F GT Tower(East), 411, Seocho-daero, Company Address company by the founder of Roche, F. Korea Ltd. Jung-gu, Seoul, Korea Company Roche Korea Co., Ltd. Address 1962 Launched business Seocho-gu, Seoul, Korea Hoffmann-La Roche 1967 Technical cooperation President Dong-Wook Oh Headquarters USA in Korea in alliance President Matt Sause Headquarters Switzerland with Jungang between F. Hoffmann-La Gasan, Gwangju, Daejeon, Daegu, Busan Pharmaceutical Seoul(Head office), Hanam QC(Quality Roche Ltd and Chong Kun Website www.pfizer.co.kr Branches Consumer healthcare: Gwangju, Daejeon, Website www.roche.co.kr Branches Dang Ltd. Daegu, Busan, Seocho, Anyang 1998 Changed name of Control) Lab 1982 Established F. Hoffmann- company to Pfizer Telephone 02-561-7200 Annual Sales about KRW 367.5 billion La Roche Ltd. Seoul office Telephone 02-317-2100 Annual Sales about KRW 681.4 billion Korea by acquiring 1983 Incorporated Roche Korea stakes held by 1998 Nominated a top company Jungang of industrial conciliation Pharmaceutical by the Ministry of Employment Product R&D Investment 2000 Integrated with Employment Product R&D Investment Employment and Labor Warner-Lambert 2011 Strategic collaboration in 697 196 7.8 USD: Billion 2010 Integrated with Wyeth 230 26 about 11.49 sales and marketing of (Based on Global HQ) 2011 President Lee Dong- KRW: trillion primary care products from Soo was elected as (Based on Global HQ) Invida in Korea a new Chairman of 2012 Signed exclusive sales KRPIA contract for 6 ETC drugs, •Lyrica: Neuropathic Pain •XALKORI: Non-small cell lung cancer 2015 Integrated with Hospira including Tamiflu® and Main Products •Mabthera: Cancer(Lymphoma), Rheumatoid arthritis •BeneFIX: Hemophilia B •Centrum: Multivitamin Main Products ® 2016 President Dong-Wook •Avastin: Cancer(Colorectal, Lung, Breast, Ovarian, cervical, metastic renal, glioblastoma) Rivotril , from Chong Kun (name/indications) •Enbrel: Rheumatoid arthritis •LIPITOR: Hyperlipidemia Oh elected (name/indications) •Xeloda: Cancer(Colorectal, Stomach and Breast cancer) Dang Ltd. •Champix: Smoking cessation •NORVASC: Hypertension •Zelboraf: Cancer(Melanoma) 2012 Launched Zeboraf™, •PREVNAR 13: Pneumococcal conjugate vaccine •Tarceva: Cancer(Lung, Pancreatic cancer) Erivedge®, Pegasis® • : Breast cancer Major R&D Status R&D Pipeline Perjeta 2013 Signed a partnership Immunology, Inflammation, Oncology, Cardiovascular disease, Metabolic disease, Nervous system •Kadcyla: Breast cancer contract for biomedicine disease, Pain therapy drugs, Vaccine •Herceptin: Cancer(breast, stomach cancer) production with Samsung Particulars •Cellcept: Immunosuppression Continuously attracted multinational clinical studies, Expanded attraction of early-phase clinical trials, •Mircera: Anemia Biologics Steadily increased partnerships in basic research area, Trained R&D manpower in Korea(including R&D •Tamiflu: Antiviral drug 2014 Signed exclusive sales and university) distribution contract for Major R&D Status Clinical Trials Major CSR •Healthy Ageing Initiatives Total about 121 projects in about 492 institutions with about 1,184 medical professionals and Roaccutane from Hanhwa Conduct a variety of Healthy Ageing Initiatives such as ‘Korea Get Old Survey’, ‘Healthy Ageing Index about 3,449 patients Dream Pharma Activities Seminar’, etc. R&D Pipeline 2015 Family Friendly certificate. •Grand Parents-Grand Children Happiness Campaign Development of 66 new drug candidates Ministry of Gender Equality Support children in grandparents-children families to manage their mental and physical health and to achieve self-development Particulars and Family ① R&D in other countries 2016 Assigned Matt Sause as • Pfizer medical research award - Produced 4 winners of Nobel Prize for Medicine Explore and recognize medical professionals who contributed to R&D of basic and clinical medical General Manager - Ranked first in healthcare industry in Dow Jones Sustainable Index for seven sciences to contribute to development of Korea’s medical community consecutive year •Pfizer Scholarship ② R&D in Korea Provide scholarships to college students in financial difficulties - Amount of R&D investment increasing continuously •KMA(Korean Medical Association)-Pfizer Prize for International Contributions to Medicine - Conducted clinical trials in Korea complying with global standards based on experiences Discover medical doctors contributing to improve doctor’s right and honor through international of U.S. FDA and EMA. cooperation - Improved level of clinical trial capabilities and technologies in Korea by attracting international Phase I clinical trial projects Awards •Good company for working mothers selected by the MOGEF and Korean Committee for Unicef(2009) •President’s Award for the equal employment by the Ministry of Employment and Labor(2011) - Status of clinical trial team in Korea was promoted to PDG site, the global R&D •Seoul Mayer’s Award for social welfare conducted by Seoul(2011) organization

Directory •President Lee, Dong-Soo received President’s Award by the Ministry of Health and Welfare(2013) Directory • •Selected as a ‘2015 Mother-friendly Workplace’ by Korean Committee for UNICEF(2015) Major CSR Healing Gallery Emotional support program for breast cancer patients who are suffering from cancer •Awards for ‘Best Companies 2015’ by Jobplanet and Fortune Korea(2015) Activities •‘Korea Prime Minister’s Volunteer’ Award-Ministry of the Interior(2016) •Children's Walk •Osong New Medicine Award’s Ethical Business Practice Category-MFDS and Korea Economic - Roche Groups' representative CSR program to support Africa children. Daily(2016) - Every year around 100 employees are participating to walk and donate for the children in •JoongAng Ilbo and Forbes Korea‘2016 ‘Korea Health Care’ Award(2016) need in Korea and Africa. •‘Pfizer Korea won the Herald Business CEO’s in ‘2017 4th Healthcare and Medial Award of Republic of Korea’(2017) Awards Family Friendly certificate. Ministry of Gender Equality and Family(2015)

78 2017 KRPIA Annual Report 2017 KRPIA Annual Report 79 sanofi-aventis Sanofi Korea Co., Ltd Pasteur Ltd. Making A World In Which No One Suffers Or Dies From Empowering Life A Vaccine Preventable Disease

2016 Korean subsidiary basis History History Company Profile Company Profile 2016 Korean subsidiary basis 1957 Started business bet. 1885 Louis Pasteur developed Company sanofi-aventis Korea Co., Ltd Address 235 Banpo-daero, Seocho-gu, Seoul Company Sanofi Pasteur Ltd. Address 235 Banpo-daero, Seoch-gu, Seoul Hoechst through rabies vaccine President Kyung-Eun(Kay) Bae Headquarters France a technical license President Baptiste de Clarens Headquarters France 1897 Marcel Merieux at Pasteur agreement with Research Institute Daejeon, Jeonju, Daegu, Busan, Gwangju, Website www.sanofi.co.kr Branches Handok Website www.sanofi.co.kr Branches Seoul, Daejeon established Merieux Jeju 1991 Established Sanofi Telephone 02-2136-9500 Annual Sales KRW 66.4 billion Research Institute in Lyon, Telephone 02-2136-9000 Annual Sales about KRW 301.9 billion Korea France 2004 Established sanofi- 1978 Established Rhone Poulenc aventis Group Korea 2005 Established R&D 1985 Merieux acquired vaccine clinical studies division of Pasteur Employment Product R&D Investment Employment Product R&D Investment organization directly 2000 Pasteur Merieux changed responsible to name to Aventis Pasteur about 63 14 about 391.5 418 45 17.5 headquarters in Korea 2005 Changed name to Sanofi KRW: billion KRW: Billion 2006 Launched sanofi- Pasteur (Based on Global HQ) aventis Korea 2010 Launched Cenovis, consumer healthcare ® Main Products •Plavix : Atherosclerosis symptoms brand in Korea Main Products •Vaxigrip Tetra: Four-Strain Influenza Vaccine • ®• ®: Diabetes (name/indications) Lantus Toujeo 2013 Received family- (name/indications) •Pentaxim: DTaP-IPV-Hib combination vaccine ® •Aprovel : Essential hypertension, Renal disease friendly company •Adacel: Tdap vaccine for teenagers and adults ® •Eloxatin : Colorectal cancer, Stomach cancer accreditation by •Avaxim 80·160U: Hepatitis A vaccine for children and adults • ®: Breast cancer, Stomach cancer, Non-small cell lung cancer, Head and Taxotere Ministry of Gender •Imovax Polio: Polio vaccine neck cancer, Ovarian cancer, Esophageal cancer and Prostate cancer Equality and Family •Menactra: Meningococcal quadrivalent conjugate vaccine 2014 Certified as Major R&D Status Clinical Trials •Imojev: Verocell Japanese encephalitis vaccine Korea Innovative Total 7 projects in 72 institutions with 221 medical professionals and 329 patients •Stamaril: Yellow fever vaccine Pharmaceutical R&D Pipeline Company(KIPC) by Myelofibrosis, Articular cartilage defects, Muscular atrophy, Diabetes, Rheumatoid Major R&D Status Clinical Trials Ministry of Health and arthritis, Atopic dermatitis and Asthma Total 2 projects in 22 institutions Welfare Particulars 2016 Received family- R&D Pipeline - Conduct R&D collaboration projects with major bio-ventures based on open innovation friendly company Clostridium Difficile(Cdiff) accreditation by - Establish ‘Premiere Network,’ international new drug clinical studies cooperation, Particulars with major clinical trials center in Korea Ministry of Gender Allies with SK Chemical to develop Pneumococcal Conjugate Vaccine - Cooperate with the MOHW to promote R&D in Korean pharmaceutical industry Equality and Family - Support education program for medical professionals and hold clinical trial academy for pre-graduate students Major CSR •Helping Hands: For the sake of the underprivileged Activities - Support free vaccination opportunity to the underprivileged including Major CSR •Green Santa homeless against flu(the largest scale in Korea) Activities Comprehensive arts & culture programs for child-patients, their sibling and caregivers with rare or chronic diseases to provide emotional and psychological care - Support for self-reliance of homeless - Support accessibility of healthcare services to small scale elementary •Green Tree Arts & culture programs for adult patients and their families with rare or chronic schools in remote areas diseases to provide emotional and psychological care Awards •Received an citation by Mayor of Seoul(2015) Directory •Received a Contribution award in KOTRA Excellent CSR contest among Directory Awards •Awarded Silver Prize in the ’2012 CSR of the Year in Asia’ in International Business Awards-Green Santa Campaign Foreign-invested companies(2014) •Awarded ‘Community Relations’ in Korea PR Awards, 2012-Green Tree Campaign •Received the Gold award of Social Contribution in Asia region in •Received ‘Family-Friendly Enterprise Certification’ from the MOGEF(Ministry of International Business Awards(2012) Gender Equity and Family) in Korea(2013) •Received an award of Domestic program of the Year in Asia-Pacific •Awarded the ‘2015 Seoul Mayor’s Award for Best Private-Public Partnerships’-Green Tree Campaign SABRE Awards(2012)

80 2017 KRPIA Annual Report 2017 KRPIA Annual Report 81 Servier Korea Shire Pharma Korea Co., Ltd. The Biotechnology A Research-based Company Pharmaceutical For Rare Dedicates To The Future Diseases and Specialties

2016 Korean subsidiary basis History History Company Profile Company Profile 2016 Korean subsidiary basis 1954 Established LES 2002 FOSRENOL® launched 5th fl., 215 Seochojungang-ro, Seocho- 18th Fl., Parnas Tower Teheran-ro, Company Servier Korea Address LABORATOIRES Company Shire Pharma Korea Co., Ltd. Address by JWP gu, Seoul, 06593, Korea SERVIER Gangnam-gu, Seoul 06164, Korea 2009 METADATE CD® President Colette ROUCHES Headquarters France 1991 Established Servier President HeeSeok Moon Headquarters Ireland launched by WhanIn Korea 2014 May: HeeSeok Moon Website www.servier.co.kr Branches Daegu Website www.shire.co.kr Annual Sales USD 61.5 million appointed as country GM of Shire Korea Telephone 02-3415-8500 Annual Sales about KRW 32.9 billion Telephone 02-2283-3500 2016 - Jun: Baxalta acquisition(Global) - Jun: RIXUBIS® launch - Jul: MEZAVANT® launch Employment Product R&D Investment Employment Product R&D Investment 2017 - Jan: Shire Korea LSD Franchise 74 6 about 1 51 12 about 880 established(REPLAGAL®, KRW: trillion USD: million VPRIV®) (Based on Global HQ) (Based on Global HQ) - May: Korea office moved to Parnas Tower 18th Fl. ® Main Products •Procoralan: Chronic heart failure, Chronic stable angina Main Products •ADVATE Anti-hemophilic Factor(Recombinant): Hemophilia A - Oct: Baxalta corporate (name/indications) •Acertil: Hypertension, Pectoris congestive heart failure, Stable coronary (name/indications) •RIXUBIS® Coagulation Factor IX(Recombinant): Hemophilia B integration(Local) artery diseases •FEIBA® Factor VIII Inhibitor Bypassing Fraction: Hemophilia A & B •Vastinan MR: Stable angina pectoris with inhibitors against coagulation factor VIII and IX • : Type 2 diabetes Diamicron MR •IMMUNATE® Human coagulation factor VIII/Human von •Fludex SR: Hypertension Willebrand Factor(VWF) complex concentrate: von Willebrand’s Disease Major R&D Status Clinical Trials •MEZAVANT® XL Mesalazine: Ulcerative Colitis Total 4 projects in about 27 institutions with about 80 medical •AGRYLIN® Anagrelide hydrochloride: Essential Thrombocythemia professionals and 217 patients •REPLAGAL® Agalsidase alfa: Fabry Disease R&D Pipeline •VPRIV® Velaglucerase alfa for injection: Gaucher Disease Cardiovascular(Angina pectoris, CHF), metabolism(diabetic •FOSRENOL® Lanthanum carbonate: Phosphate Binding Agent nephropathy), cancer(NSCLC) •METADATE CD® Methylphenidate hydrochloride: ADHD •Firazyr® Icatibant injection: Hereditary Angioedema(HAE) Major CSR •Sharing kimchi with love •Onivyde® Irinotecan liposome injection: Pancreatic cancer Activities Employees took part in the event of making kimchi for the winter arranged by Yeongdeungpo Borough Office to deliver to neglected and low-income families and social welfare facilities Major R&D Status Clinical Trials Total 7 projects in 22 institutions with 22 medical professionals and 50 •Mutual Cooperation patients involved Han Wha Pharma Co., Ltd./Kwang Dong Pharmaceutical Co., Ltd./ Yungjin Pharmaceutical Co., Ltd./Jeil Pharmaceutical Co., Ltd./ R&D Pipeline KyungDong Pharm. Co., Ltd./SK Chemicals Short Bowel Syndrome, Hypoparathyroidism, Dry Eye Syndrome Directory Directory

Major CSR •Global Day of Service Awards •Received an Award in Great Place to Work Award: GPTW Korea(2016) Activities An annual event upon which global Shire employees together take part in various voluntary services, and look beyond their own lives towards the communities and needs of others

82 2017 KRPIA Annual Report 2017 KRPIA Annual Report 83 Korea UCB Zuellig Pharma Korea Ltd. Co., Ltd. The Patient Centric Global Making Healthcare Biopharmaceutical Leader More Accessible

2016 Korean subsidiary basis History History Company Profile Company Profile 2016 Korean subsidiary basis 1918 Established the 1997 Established Korea Logistics 4FL., A+ Asset Tower, 369, Gangnam- 3F LS Yongsan Tower, Hangang-ro 92, Company Korea UCB Co., Ltd. Address company Company Zuellig Pharma Korea Ltd. Address Services Co. daero, Seocho-gu, Seoul, Korea 1960 Developed as Yongsan-gu, Seoul 2000 Change the company’s President Lee Kate Headquarters Belgium research leader in President Mr. Christophe Piganiol Headquarters Singapore name to Zuellig Pharma biotechnology sector Korea Ltd. Website www.ucbkorea.co.kr Branches Seoul 1989 Established subsidiary 6 Sales offices(Seoul, Incheon, Daejeon 2009 Launched Bonded& in Korea ,Daegu, Busan, Gwangju) Importer warehouse Telephone 02-534-3580 Annual Sales about KRW 60 billion Website www.zuelligpharma.com Branches 1992 Launched Allergy Drug, 6 Distribution Centers(Hwasung I•II, service Zyrtec Ansung I•II•III, Seoul(Gimpo)) 2010 Strategic collaboration with 2004 Rearranged the Kyung Dong Sa/Launched organization as pure Telephone 02-2006-0600 Annual Sales KRW 889 billion vaccine service biopharmaceutical 2011 Launched Warehouse Employment Product company by acquiring service for Medical Device the UK biotechnology Products 52 12 company, CellTech Employment 2014 Launched Patient Solution 2007 Reorganized UCB Service as future-oriented 286 company and carried reformation 2009 The 20th anniversary Major R&D Status Particulars 2013 Launched drugs for Main Products •Keppra: Epilepsy - ISO 9001·2000 certification multiple sclerosis, (name/indications) Avonex and Fampyra - ISMS certification - KGSP(Korean Goods Supplying Practices) - GSDP(Good Storage Distribution Practices) Major R&D Status R&D Pipeline - CGMP(Current Good Manufacturing Practice) Treatments for Central nerve and immunologic disorders including Epilepsy, Rheumatoid arthritis and Systemic lupus erythematosus Major CSR •The Number of Participants & Hours per year Particulars Activities - Participating Employees: about 200 - Received ‘BioAlps Award’ for devoting to advanced scientific research - Participating Institutions: about 1,000 pharmacies - Received ‘BEL20 Best Performance Award’ as a company bringing the - Hours: about 600 hours best performance at Euronext •The Number of Beneficiaries & per year - Received ‘Excellence in Epilepsy Journalism Award’ co-sponsored by - Served People: about 2,000 European Mediscience Company - Served Institutions: about 1,000

Zuellig with Love •Breast Cancer Awareness Campaign Major CSR •Art Bus Project for Children with epilepsy Hand out breast self-exam teaching leaflets, join pick ribbon marathon, wear Activities •Picnic of Hope for children with epilepsy the pink ribbon badges and run pink truck during the campaign season •Volunteer service on the World Multiple Sclerosis Day •Baking with Love voluntary work •Mutual Cooperation Breads baked and delivered by employees for the low-income families Yuhan Corporation, Zuellig Pharma Korea Ltd •Distribution of "Life Plus", the health & pharmaceutical journal at

Directory pharmacies Directory Contain data about epidemic disease(i.e. MERS) and prevention •Visit orphanages and senior citizens living alone for support •Making a 1004 Donation for helping children with cancer •Pink Ribbon Campaign Facebook Event SNS event held to increase the awareness of breast cancer

84 2017 KRPIA Annual Report 2017 KRPIA Annual Report 85 Member Currently, the subsidiaries of 40 global pharmaceutical companies in Korea have joined Companies KRPIA as member companies. These global pharmaceutical companies of KRPIA are leading the global development of new drugs based on R&D activities.

Actelion Pharmaceuticals Abbott Korea AbbVie Korea Allergan Korea Ltd. Amgen Korea Korea Ltd.

AstraZeneca Korea Bayer Korea BMS Pharmaceutical Korea Ltd. Boehringer Ingelheim Korea Bracco Imaging Korea

Celgene co. DKSH Korea, Ltd. GE Healthcare Korea Genzyme Korea Co., Ltd Gilead Sciences Korea

GSK Korea Guerbet Korea Imaging Solutions Korea Ltd. Ipsen Korea Ltd. Janssen Korea

Johnson & Johnson S&D LLC. LEO Pharma Korea Lilly Korea Lundbeck Korea A. Menarini Korea Ltd.

Novo Nordisk Pharma Merck Ltd. Korea MSD Korea Ltd. Mundipharma Korea Ltd. Novartis Korea Korea Ltd.

Pfizer Pharmaceuticals ONO Pharma Korea Co., LTD. OXY Reckitt Benckiser LLC Roche Korea Co., Ltd. sanofi-aventis Korea Co., Ltd Korea Ltd.

Sanofi Pasteur Ltd. Servier Korea Shire Pharma Korea Co., Ltd. Korea UCB Co., Ltd. Zuellig Pharma Korea Ltd.

2017 KRPIA Annual Report New Medicine, New Hope

Published on November, 2017 Address 4F 366, Hangang-daero, Yongsan-gu, Seoul Published by Korea Research-based Pharmaceutical Website www.krpia.or.kr Industry Association(KRPIA) Tel. (02)456-8553